Schedule Update - effective 1 July 2012 (text extract)

This is the text extract for Schedule Update - effective 1 July 2012, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 July 2012

Cumulative for May, June and July 2012 Section H cumulative for April, May, June and July 2012

Only

annually for hard copy Schedule and Updates

$55

www. schedule. co.nz

today

to receive electronic and/or hard copy

Contents

Summary of PHARMAC decisions effective 1 July 2012 ................................. 3 Vaccines ........................................................................................................ 6 No more Close Control from 1 July 2012 ...................................................... 6 Buprenorphine with naloxone (Suboxone) new listing .................................. 8 Dabigatran removal of OP restriction and delisting of bottle presentation ... 8 New low dose combined oral contraceptive brand – Ava 20 ED ................... 9 Macrogol 3350 powder – delay in listing ...................................................... 9 Upcoming BSF payments for ursodeoxycholic acid and rizatriptan ............... 9 Sole Supply reinstated for amoxycillin clavulanate (Curam Duo) ................... 9 Felodipine long-acting tablet 2.5 mg – removal of restriction ..................... 10 Premature birth formula - Special Authority change ................................... 10 Hospital Sole Supply (HSS) expiry date ........................................................ 10 News In brief ............................................................................................... 11 Tender News ................................................................................................ 12 Looking Forward ......................................................................................... 12 Sole Subsidised Supply products cumulative to July 2012 ........................... 14 New Listings ................................................................................................ 22 Changes to Restrictions ............................................................................... 26 Changes to Subsidy and Manufacturer’s Price............................................. 36 Changes to General Rules............................................................................ 42 Changes to Brand Name ............................................................................. 47 Changes to Sole Subsidised Supply ............................................................. 48 Delisted Items ............................................................................................. 49 Items to be Delisted .................................................................................... 51 Section H changes to Part II ........................................................................ 54 Section H changes to Part III........................................................................ 62 Index ........................................................................................................... 63

Summary of PHARMAC decisions

EFFECTIVE 1 JULY 2012 New listings (pages 22-24) • Insulin aspart (NovoMix 30 FlexPen) inj 100 iu per ml, 3 ml prefilled pen • Felodipine (Plendil ER) tab long-acting 5 mg and 10 mg • Ethinyloestradiol with levonorgestrel (Ava 20 ED) tab 20 µg with levonorgestrel 100 µg and 7 inert tab – up to 84 tab available on a PSO • Diptheria and tetanus vaccine (ADT Booster) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Diptheria, tetanus, and pertussis vaccine (Boostrix) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Diptheria, tetanus, pertussis, and polio vaccine (Infanrix-IPV) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Diptheria, tetanus, pertussis, polio, hepatitis B, and haemophilus influenzae type B vaccine (Infanrix-hexa) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Haemophilus influenzae type B (Act-HIB) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Hepatitis B vaccine (HBvaxPro) inj 0.5 ml – Hospital pharmacy [Xpharm] access criteria apply • Human papillomavirus vaccine (Gardasil) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Measles, mumps and rubella vaccine (M-M-R II) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Meningococcal A, C, Y and W-135 vaccine (Menomune) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Pneumococcal polysaccharide vaccine (Pneumovax 23) inj 0.5 ml – Hospital pharmacy [Xpharm] - access criteria apply • Pneumococcal vaccine (Synflorix) inj 0.5 ml – Hospital pharmacy [Xpharm] access criteria apply • Bacillus Calmette-Guerin vaccine (BCG Vaccine) inj multi-dose vial (10 dose) 0.5 ml – Hospital pharmacy [Xpharm] – access criteria apply • Pneumococcal (PCV13) vaccine (Prevenar 13) inj 0.5 ml – Hospital pharmacy [Xpharm] – access criteria apply • Buprenorphine with naloxone (Suboxone) tab sublingual 2 mg with naloxone 0.5 mg and 8 mg with naloxone 2 mg – Special Authority – Retail pharmacy – only on a controlled drug form – no patient co-payment payable

Summary of PHARMAC decisions – effective 1 July 2012 (continued) Changes to restrictions (pages 26-28) • Dabigatran (Pradaxa) cap 75 mg, 110 mg and 150 mg – removal of OP from bottle packs – removal of dabigatran not being funded Close Control in amounts less than 4 weeks treatment • Felodipine (Plendil ER) tab long-acting 2.5 mg – removal of no more than 1 tab per day • Nicotine (Habitrol) patch 7 mg, 14 mg, and 21 mg; lozenge 1 mg and 2 mg; and gum (classic, fruit and mint) 2 mg and 4 mg – dispensing frequency restriction amendment • Varenicline tartrate (Champix) tab 1 mg, and tab 0.5 mg x 11 and 1 mg x 14 – dispensing frequency restriction amendment • Premature birth formula (S26LBW Gold RTF) liquid, 100 ml OP – Special Authority amendment • Amino acid formula (Elecare, Elecare LCP, Neocate, Neocate Advance, Neocate Gold, and Vivonex Pediatric) powder – Special Authority amendment • Extensively hydrolysed formula (Pepti Junior Gold) powder – Special Authority amendment • Close Control rule – removed • Dispensing Frequency Rule – addition • Access Exemption Rule – amended access criteria Increased subsidy (pages 36-39) • Glucagon hydrochloride (Glucagen Hypokit) inj 1 mg syringe kit • Oral feed (powder) (Ensure) powder chocolate and vanilla, 900 g OP Decreased subsidy (pages 36-39) • Mesalazine (Pentasa) enema 1 g per 100 ml • Pioglitazone (Pizaccord) tab 15 mg, 30 mg and 45 mg • Hydroxocobalamin (ABM Hydroxocobalamin) inj 1 mg per ml, 1 ml • Enoxaparin sodium (Clexane) inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg and 150 mg • Felodipine (Plendil ER) tab long-acting 2.5 mg • Furosemide (Diurin 40) tab 40 mg • Crotamiton (Itch-Soothe) crm 10% • Mometasone furoate (m-Mometasone) crm 0.1% and oint 0.1%, 15 g OP and 45 g OP • Acitretin (Neotigason) cap 10 mg and 25 mg • Norethisterone (Noriday 28) tab 350 µg • Cabergoline (Dostinex) tab 0.5 mg, 2 and 8 tab packs • Roxithromycin (Arrow-Roxithromycin) tab 150 mg and 300 mg

All decisions related to news items are effective from 1 September unless otherwise indicated 4

Summary of PHARMAC decisions – effective 1 July 2012 (continued) • Flucloxacillin sodium (AFT) grans for oral liq 125 mg per 5 ml and 250 mg per 5 ml • Gentamicin sulphate (Pfizer) inj 40 mg per ml, 2 ml • Etidronate disodium (Arrow-Etidronate) tab 200 mg • Fentanyl citrate (Boucher and Muir) inj 50 µg per ml, 2 ml and 10 ml • Methadone hydrochloride oral liquid 2 mg per ml (Biodone) and 10 mg per ml (Biodone Extra Forte) • Mirtazapine (Avanza) tab 30 mg and 45 mg • Venlafaxine tab 37.5 mg, 75 mg and 150 mg (Arrow-Venlafaxine XR) and cap 37.5 mg, 75 mg and 150 mg (Efexor XR) • Cyclizine hydrochloride (Nausicalm) tab 50 mg • Lithium carbonate (Lithicarb FC) tab 250 mg and 400 mg • Quetiapine (Quetapel) tab 25 mg, 100 mg, 200 mg and 300 mg • Risperidone (Risperdal) tab 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, and oral liq 1 mg per ml • Idarubicin hydrochloride inj 5 mg and 10 mg (Zavedos) and inj 1 mg for ECP (Baxter) • Vinorelbine inj 10 mg per ml, 1 ml and 5 ml (Navelbine) and inj 1 mg for ECP (Baxter) • Promethazine hydrochloride (Allersoothe) tab 10 mg and 25 mg • Eformoterol fumarate powder for inhalation, 6 µg per dose, breath activated (Oxis Turbuhaler) and powder for inhalation, 12 µg per dose and monodose device (Foradil) • Chloramphenicol (Chlorafast) eye drops 0.5% • Latanoprost (Hysite) eye drops 50 µg per ml, 2.5 ml OP • Brimonidine tartrate (AFT) eye drops 0.2%, 5 ml OP • Amino acid formula powder unflavoured, 400 g OP (Elecare and Elecare LCP), and powder vanilla, 400 g OP (Elecare)

All decisions related to news items are effective from 1 September unless otherwise indicated 5

6 Pharmaceutical Schedule - Update News

Vaccines

From 1 July 2012, PHARMAC will be listing vaccines on the Pharmaceutical Schedule following it becoming responsible for the funding. As the vaccines are delivered mostly by General Practice and school based programmes, the vaccines will continue to be supplied free of charge to those who administer them and will be listed as XPharm on the Pharmaceutical Schedule at a subsidy of $0.00. The Immunisation Programme will continue to be run by the Ministry of Health, and ESR will continue to manage the distribution of vaccines. There will be no change to the current payment mechanisms around the Immunisation Benefit. Going forward PHARMAC will be responsible for considering any changes to the range of funded vaccines, including the eligibility criteria and funding of new vaccines.

No more Close Control from 1 July 2012

Changes to dispensing frequencies are occurring from 1 July 2012. The Close Control rule is being replaced with the Dispensing Frequency Rule and pharmacists will gain more flexibility with dispensing frequencies for their patients. These are explained in more detail below. ‘Close Control’ becomes ‘Dispensing Frequency’ The Dispensing Frequency Rule replaces Close Control from 1 July 2012. The Dispensing Frequency Rule is grouped into three sections: • Frequency of dispensing for persons in residential care – no changes • Flexible periods of supply for trial periods or safety – changes explained below • Pharmaceutical supply management – no changes Flexible periods of supply for trial periods or safety The section “intellectually impaired, frail, infirm or unable to manage their medicine” has been removed; and is replaced by the Long-Term Condition (LTC) service in the Community Pharmacy Services Agreement. Patients who are eligible for the LTC service can have more frequent dispensing. This is determined by the pharmacist. For patients not eligible under the LTC service (defined

Pharmaceutical Schedule - Update News

as ‘Core’ patients under the Pharmacy Services Agreement) who require more frequent than monthly dispensing, the pharmacist needs to get verbal confirmation from the prescriber. Codeine and buprenorphine with naloxone (Suboxone) have been added to the list of safety medicines. Prescribers no long need to endorse safety medicines. They do need to specify the maximum quantity or period of supply to be dispensed at any one time. Pharmacists are NOT eligible to initiate patients for more frequent dispensings for medicines on the safety list. Medicines co-prescribed with medicines on the safety list, can be dispensed at the same frequency. This is determined by the pharmacist and annotated on the script accordingly. Prescribers no longer have to initial each trial medicine, but need to endorse with ‘trial period’ or ‘trial’. Pharmacists cannot initiate patients for trial periods. Access Exemption changes Pharmacists can now initiate ‘Certified Exemptions’ for medicines listed in the Pharmaceutical Schedule marked with an s, as well as prescribers. Flexible Dispensing for pharmacists A new rule has been added to give pharmacists more flexibility when dispensing some medicines – Section F: Part III (Flexible and Variable Dispensing Periods for Pharmacy). This allows pharmacists to use variable dispensing periods for non Stat

medicines (those not identified with a ❋) in the following situations: • Stock management, where the original pack(s) result in dispensing greater than 30 days supply; or • To synchronise a patient's medication where multiple medicines result in uneven supply periods. Pharmacists must annotate the prescription with the reason for flexible dispensing. Pharmacists cannot dispense greater than the total period of supply. These changes are not mandatory. If a pharmacist has concern about the clinical appropriateness of altering the dispensing frequency, they should check with the patients prescriber. Generally where a prescriber has endorsed the prescription for more frequent dispensing than normal, it would not be good clinical judgement to change the dispensing frequency unless the pharmacist has good reason to believe the patient is stable and compliant. If prescribers continue to write Close Control and the pharmacist believes this is out of habit, the pharmacist should contact them in the first instance to ensure there is not a clinical reason why the patient should receive more frequent dispensing. This need to be recorded in the first instance but not for future prescriptions for the same medicine and same patient. Further information and resources can be found on our website www.pharmac.govt.nz/ccc

Pharmaceutical Schedule - Update News

Buprenorphine with naloxone (Suboxone) new listing

From 1 July 2012, buprenorphine with naloxone sublingual tablets, Suboxone, will be listed fully subsidised subject to Special Authority criteria for detoxification and maintenance of treatment of opioid dependence. There will be no patient co-payment required and from the listing date, pharmacies that dispense buprenorphine with naloxone will be reimbursed as per their Pharmacy Services Agreement; at the same level that currently applies to the dispensing of methadone. Buprenorphine with naloxone sublingual tablets must be prescribed on a controlled drug form. It has also been added to the Safety List in the Dispensing Frequency rule which automatically enables it to be dispensed more frequently than monthly.

Dabigatran removal of OP restriction and delisting of bottle presentation

The Original Pack (OP) restriction that applies to the bottle presentations of dabigatran (Pradaxa) 110 mg and 150 mg capsules, and to the blister pack of the 75 mg presentation will be removed from 1 July 2012. Pharmacists will no longer be able to claim for an entire pack if dispensing only a portion of the pack. Boehringer Ingleheim has been supplying Pradaxa in blister packs, listed without an OP restriction, from 1 April 2012 and has now discontinued supplying the bottle presentation. Bottle presentations of 110mg and 150 mg capsules will be delisted from 1 January 2013. The restriction that dabigatran will not be funded Close Control in amounts less than 4 weeks of treatment will also be removed from 1 July 2012.

Pharmaceutical Schedule - Update News

New low dose combined oral contraceptive brand – Ava 20 ED

As a result of the tender there will be a new brand of low dose ethinyloestradiol 20 µg with levonorgestrel 100 µg tablets listing on the Pharmaceutical Schedule. Ava 20 ED (ethinyloestradiol 20 µg ethinyloestradiol with 100 µg levonorgestrel and 7 inert tablets) supplied by Arrow Pharmaceuticals, will be listed fully subsidised from 1 July 2012 and will become the sole subsidised brand from 1 December 2012.

Macrogol 3350 powder – delay in listing

There has been a further delay in the listing of Lax-Sachets brand of macrogol 3350 powder supplied by AFT Pharmaceuticals. This product will now be listed from 1 August 2012, the Movicol brand will now be referenced price from 1 October 2012 and Lax-Sachets will commence sole supply on 1 January 2013.

Upcoming BSF payments for ursodeoxycholic acid and rizatriptan

Brand Switch Fee (BSF) payments for pharmacies will be payable for dispensings of ursodeoxycholic acid (Ursosan) and rizatriptan (Rizamelt) from 1 August 2012 until 1 November 2012.

Sole Supply reinstated for amoxycillin clavulanate (Curam Duo)

From 1 December 2012, Curam Duo will become the sole subsidised brand of amoxicillin clavulanate tablets. The listing of Curam Duo was delayed due to the supplier, Sandoz, being unable to supply at the time. Sandoz began supplying Curam Duo from March 2012. Synermox will be delisted 1 December 2012.

10 Pharmaceutical Schedule - Update News

Felodipine long-acting tablet 2.5 mg – removal of restriction

The daily maximum restriction that applies to felodipine 2.5 mg long-acting tablets will be removed from 1 July 2012. The ‘no more than 1 tablet per day’ restriction will be removed which will permit the subsidy of more than 1 felodipine (Plendil ER) 2.5 mg long-acting tablet per day.

Premature birth formula - Special Authority change

The Special Authority criteria that currently applies to Premature Birth Formula (SA1109), brand name S26LBW Gold RTF, has been amended so that no new approvals will be given for this product. Patients with a current Special Authority approval will continue to be able to access a subsidy for S26LBW Gold RTF and will have ceased treatment when it S26LBW Gold RFT is ultimately delisted from 1 April 2013. For new patients an alternative product, Preterm Post-Discharge Infant Formula (S-26 Gold Premgro) was listed fully subsidised under Special Authority criteria from 1 April 2012.

Hospital Sole Supply (HSS) expiry date

The end of June each year sees the expiry of many sole supply contracts. This year is no different. For items listed in Part II of Section H that expire on 30 June 2012, and where there are no further changes to the listing of a product, the HSS expiry have not been reflected in this Update as they have in previous years.

Pharmaceutical Schedule - Update News

News In brief

• The Regitine brand of phentolamine mesylate injection 10 mg per ml will be delisted from 1 January 2013 due to supplier discontinuation. • From 1 January 2013, the Zerit brand of stavudine (D4T) 30 mg capsules will be delisted due to supplier discontinuation. The 40 mg presentation will remain subsdised. • The Apo-Bromocriptine brand of bromocriptine supplied by Apotex will be delisted from 1 January 2013 due to supplier discontinuation. The 2.5 mg capsules will remain listed • Pfizer’s new brand of atorvastatin tablets, Zarator, will be listed fully subsidised from 1 August 2012. Zarator has been awarded sole subsidised supply from 1 January 2013. All strengths of atorvastatin brands Lipitor and Dr Reddy’s Atorvastatin, will have a subsidy decrease from 1 October 2012 and be delisted from 1 January 2013. • The subsidy for candesartan (Candestar and Atacand) tablets, all strengths, will reduce from 1 August 2012. Candestar has been awarded sole subsidised supply from 1 November 2012. Atacand will be delisted from 1 November 2012. The daily dose dispensing restrictions that currently apply to candesartan will be removed from 1 August 2012. The Special Authority criteria for candesartan will also be amended from 1 August. • Eformoterol fumarate powder for inhalation 6 µg per dose, Oxis Turbuhaler and 12 µg per dose, Foradil, will have a further subsidy decrease from 1 July 2012. This will result in an increased patient part-charge. • AstraZeneca has changed the price of all its strengths of metoprolol succinate long-acting tablets (Betaloc CR). This will result in an increased patient part-charge for most patients as this brand is not fully subsidised. Betaloc CR long-acting tablets will be delisted from 1 September 2012. Metoprolol – AFT CR has been awarded sole subsidised supply from 1 September 2012. • The price and subsidy for the Elecare brands of amino acid infant formula is to be reduced from 1 July 2012. The price and subsidy for Neocate will also decrease from 1 August as a result of reference pricing and a price drop from the supplier. Please note the supplier has notified that it will be reducing the price of Neocate from 12th July. This means that both Elecare and Neocate will remain fully funded.

Tender News

Sole Subsidised Supply changes – effective 1 August 2012

Chemical Name Bisoprolol fumarate Bisoprolol fumarate Bisoprolol fumarate Clindamycin Metoprolol tartrate Metoprolol tartrate Metoprolol tartrate Metoprolol tartrate Octreotide (somatostatin analogue) Octreotide (somatostatin analogue) Octreotide (somatostatin analogue) Rizatriptan Tetrabenazine Ursodeoxycholic acid Zinc and castor oil Presentation; Pack size Tab 2.5 mg; 30 tab Tab 5 mg; 30 tab Tab 10 mg; 30 tab Cap hydrochloride 150 mg; 16 cap Inj 1 mg per ml, 5 ml; 5 inj Tab 50 mg; 100 tab Tab 100 mg; 60 tab Tab long-acting 200 mg; 28 tab Inj 50 µg per ml, 1 ml; 5 inj Inj 100 µg per ml, 1 ml; 5 inj Inj 500 µg per ml, 1 ml; 5 inj Tab orodispersible 10 mg; 30 tab Tab 25 mg; 112 tab Cap 250 mg; 100 cap Oint BP; 500 g Sole Subsidised Supply brand (and supplier) Bosvate (Douglas) Bosvate (Douglas) Bosvate (Douglas) Clindamycin ABM (ABM) Lopresor (Novartis) Lopresor (Novartis) Lopresor (Novartis) Slow-Lopresor (Novartis) Octreotide MaxRx (Max Health) Octreotide MaxRx (Max Health) Octreotide MaxRx (Max Health) Rizamelt (Mylan) Motetis (AFT) Ursosan (ABM) Multichem (Multichem)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Decisions for implementation 1 August 2012 • Amino acid formula powder (Neocate and Neocate LCP) 400 g OP, powder tropical (Neocate Advance) 400 g OP, powder unflavoured(Neocate Advance and Neocate Gold) 400 g OP, and powder vanilla (Neocate Advance) 400 g OP – price and subsidy decrease • Atorvastatin (Zarator) tab 10 mg, 20 mg, 40 mg and 80 mg – new listing • Candesartan (Candestar and Atacand) tab 4 mg, 8 mg, 16 mg and 32 mg – removal of daily dose restriction, amended Special Authority criteria and subsidy reduction. Candestar will remain fully subsidised • Rizatriptan (Rizamelt) tab orodispersible 10 mg – brand switch fee • Ursodeoxycholic acid (Ursosan) tab 250 mg – brand switch fee

Possible decisions for implementation 1 August 2012 • Eformoterol fumarate powder for inhalation 6 µg per dose, breath activated (Oxis Turbuhaler) and powder for inhalation 12 µg per does, and monodose device (Foradil) – removal of repeat rule • Gefitinib (Iressa) tab 250 mg – new listing with Special Authority criteria • Ivermectin (Stromectol) tab 3 mg – new listing with Special Authority criteria • Montelukast sodium (Singulair) tab 10 mg, and chewable tab 4 mg and 5 mg – new listing with Special Authority citeria Possible decisions for implementation 1 September 2012 • Atorvastatin (Dr Reddy’s Atorvastatin) tab 10 mg, 20 mg, 40 mg and 80 mg – subsidy decrease

Sole Subsidised Supply Products – cumulative to July 2012

Generic Name

Abacavir sulphate Acetazolamide Aciclovir Allopurinol Amantadine hydrochloride Aminophylline Amitriptyline Amlodipine Amoxycillin Aqueous cream Ascorbic acid Aspirin Azathioprine Bendrofluazide Benzylpenicillin sodium (Penicillin G) Betaxolol hydrochloride Bicalutamide Bisacodyl Calcitonin Calcium carbonate Calcium folinate Captopril Cefaclor monohydrate Cefazolin sodium Ceftriaxone sodium Cefuroxime sodium Cetomacrogol

Presentation

Oral liq 20 mg per ml Tab 300 mg Tab 250 mg Tab dispersible 200 mg, 400 mg & 800 mg Tab 100 mg & 300 mg Cap 100 mg Inj 25 mg per ml, 10 ml Tab 25 mg & 50 mg Tab 2.5 mg Tab 5 mg & 10 mg Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg Crm Tab 100 mg Tab 100 mg Tab dispersible 300 mg Tab 50 mg Inj 50 mg Tab 2.5 mg & 5 mg Inj 600 mg Eye drops 0.5% Eye drops 0.25% Tab 50 mg Tab 5 mg Inj 100 iu per ml, 1 ml Tab 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental) Tab 15 mg Tab 12.5 mg, 25 mg & 50 mg Oral liq 5 mg per ml Grans for oral liq 125 mg per 5 ml Inj 500 mg & 1 g Inj 500 mg Inj 1 g Inj 750 mg Crm BP

Brand Name Expiry Date*

Ziagen Ziagen Diamox Lovir Apo-Allopurinol Symmetrel DBL Aminophylline Amitrip Apo-Amlodipine Apo-Amlodipine Ibiamox Alphamox AFT Vitala-C Ethics Aspirin EC Ethics Aspirin Imuprine Imuran ArrowBendrofluazide Sandoz Betoptic Betoptic S Bicalaccord Lax-Tab Miacalcic Arrow-Calcium Calsource DBL Leucovorin Calcium m-Captopril Capoten Ranbaxy-Cefaclor AFT Veracol Aspen Ceftriaxone Multichem PSM 2014 2014 2013 2014 2014 2014 2014 2014 2014 2013 2014 2013 2013 2013 2014 2014 2014 2014 2013 2014 2014 2014 2013 2013 2014 2013 2014 2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to July 2012

Generic Name

Cetirizine hydrochloride Chlorhexidine gluconate Cilazapril Cilazapril with hydrochlorothiazide Ciprofloxacin Citalopram hydrobromide Clarithromycin Clopidogrel Clotrimazole

Presentation

Oral liq 1 mg per ml Tab 10 mg Soln 4% Tab 0.5 mg, 2.5 mg & 5 mg Tab 5 mg with hydrochlorothiazide 12.5 mg Tab 250 mg, 500 mg & 750 mg Tab 20 mg Tab 500 mg Tab 250 mg Tab 75 mg Crm 1% Vaginal crm 1% with applicator Vaginal crm 2% with applicator Soln BP Tab 500 µg Powder for soln for oral use 4.4 g Tab 50 mg Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs Nasal spray 10 µg per dose Eye oint 0.1% Eye drops 0.1% Inj 4 mg per ml, 1 ml & 2 ml

Brand Name Expiry Date*

Cetirizine - AFT Zetop Orion Zapril Inhibace Plus Cipflox Arrow-Citalopram Apo-Clarithromycin Apo-Clarithromycin Apo-Clopidogrel Clomazol Clomazol Clomazol Midwest Colgout Electral Cycloblastin Ginet 84 Desmopressin-PH&T Maxidex Maxidex Hospira Maxitrol Maxitrol 2014 2014 2013 2013 2014 2014 2014 2013 2014 2013 2013 2013 2013 2013 2014 2014 2014 2013 2013 2014

Coal tar Colchicine Compound electrolytes Cyclophosphamide Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone Dexamethasone sodium phosphate

Dexamethasone with neomycin Eye oint 0.1% with neomycin sulphate and polymyxin b sulphate 0.35% and polymyxin B sulphate 6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Dextrose Dextrose with electrolytes Inj 50%, 10 ml Soln with electrolytes

Biomed Pedialyte – Fruit Pedialyte – Bubblegum Pedialyte – Plain Voltaren Voltaren Ophtha Voltaren DHC Continus Pytazen SR

2014 2013

Diclofenac sodium

Inj 25 mg per ml, 3 ml Eye drops 1 mg per ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Tab long-acting 150 mg

2014

Dihydrocodeine tartrate Dipyridamole

2013 2014

Sole Subsidised Supply Products – cumulative to July 2012

Generic Name

Docusate sodium Docusate sodium with sennosides Doxazosin mesylate Doxycycline hydrochloride Emulsifying ointment Ergometrine maleate Escitalopram Exemestane Fentanyl

Presentation

Cap 50 mg Cap 120 mg Tab 50 mg with total sennosides 8 mg Tab 2 mg & 4 mg Tab 100 mg Oint BP Inj 500 µg per ml, 1 ml Tab 10 mg & 20 mg Tab 25 mg Transdermal patch 12.5 µg per hour, 25 µg per hour, 50 µg per hour, 75 µg per hour, 100 µg per hour Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) Tab 5 mg Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Cap 20 mg Tab dispersible 20 mg, scored Tab 250 mg Metered aqueous nasal spray, 50 µg per dose Inj 10 mg per ml, 2 ml Crm 2% Oint 2% Cap 100 mg, 300 mg & 400 mg Tab 600 mg Tab 80 mg Liquid Aerosol spray 400 µg per dose TDDS 5 mg & 10 mg Tab 600 µg Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Crm 1% Powder Inj 50 mg per ml, 1 ml

Brand Name Expiry Date*

Laxofast 50 Laxofast 120 Laxsol Apo-Doxazosin Doxine AFT DBL Ergometrine Loxalate Aromasin Mylan Fentanyl Patch Ferodan Rex Medical Flucloxin Ozole Fluox Fluox Flutamin Flixonase Hayfever & Allergy Frusemide-Claris Foban Foban Nupentin Lipazil Apo-Gliclazide healthE Glytrin Nitroderm TTS Lycinate Serenace Serenace Serenace Pharmacy Health ABM Solu-Cortef 2014 2013 2014 2014 2014 2014 2013 2014 2013

Ferrous sulphate Finasteride Flucloxacillin sodium Fluconazole Fluoxetine hydrochloride Flutamide Fluticasone propionate Furosemide Fusidic acid Gabapentin Gemfibrozil Gliclazide Glycerol Glyceryl trinitrate

2013 2014 2014 2014 2013 2013 31/1/13 2013 2013 31/7/12 2013 2014 2013 2014

Haloperidol

2013

Hydrocortisone

2014 2013

Sole Subsidised Supply Products – cumulative to July 2012

Generic Name

Hydrocortisone with miconazole Hydrocortisone with wool fat and mineral oil Hyoscine N-butylbromide Ibuprofen

Presentation

Crm 1% with miconazole nitrate 2% Lotn 1% with wool fat hydrous 3% and mineral oil Inj 20 mg, 1 ml Tab 10 mg Tab 200 mg Tab long-acting 800 mg Oral liq 100 mg per 5 ml Crm 5% Tab 2.5 mg Aqueous nasal spray, 0.03%, 15 ml OP Nebuliser soln, 250 µg per ml, 1 ml & 2 ml Inj 50 mg per ml, 2 ml Tab 20 mg Tab long-acting 40 mg Cap 100 mg Shampoo 2% Oral liq 10 g per 15 ml Oral liq 10 mg per ml Tab 150 mg Subdermal implant (2 x 75 mg rods) Viscous soln 2% Inj 1%, 5 ml & 20 ml Crm 2.5% with prilocaine 2.5% (5 g tubes) Crm 2.5% with prilocaine 2.5%; 30 g OP Cap 250 mg Eye drops 0.1% Cap 2 mg Oral liq 1 mg per ml Tab 10 mg Tab 1 mg & 2.5 mg Tab 12.5 mg, 25 mg, 50 mg & 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg

Brand Name Expiry Date*

Micreme H DP Lotn HC Buscopan Gastrosoothe Arrowcare Brufen SR Fenpaed Aldara Dapa-Tabs Univent Univent Ferrum H Ismo 20 Corangin Itrazole Sebizole Laevolac 3TC 3TC Jadelle Xylocaine Viscous Xylocaine EMLA EMLA Douglas Lomide Diamide Relief Lorapaed Loraclear Hayfever Relief Ativan Lostaar Arrow-Losartan & Hydroclorothiazide 2014 2014 2013 2013 2014 2014 2013 2014 2013 2013 31/12/13 2014 2013 2013 2013 2014 2014 2014 2013 2014 2013 2013

Imiquimod Indapamide Ipratropium bromide

Iron polymaltose Isosorbide mononitrate Itraconazole Ketoconazole Lactulose Lamivudine Levonorgestrel Lignocaine hydrochloride Lignocaine with prilocaine

Lithium carbonate Lodoxamide trometamol Loperamide hydrochloride Loratadine

Lorazepam Losartan Losartan with hydrochlorothiazide

2013 2014 2014

Sole Subsidised Supply Products – cumulative to July 2012

Generic Name

Malathion Mask for spacer device Mebendazole Mebeverine hydrochloride Mercaptopurine Mesalazine Methadone hydrochloride Methotrexate Metoclopramide hydrochloride Miconazole nitrate Morphine sulphate

Presentation

Liq 0.5% Shampoo 1% Size 2 Tab 100 mg Tab 135 mg Tab 50 mg Suppos 500 mg Tab 5 mg Inj 25 mg per ml, 2 ml & 20 ml Inj 5 mg per ml, 2 ml Tab 10 mg Crm 2% Inj 5 mg per ml, 1 ml Inj 10 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg

Brand Name Expiry Date*

A-Lices A-Lices EZ-fit Paediatric Mask De-Worm Colofac Purinethol Asacol Methatabs Hospira Pfizer Metamide Multichem DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate Arrow-Morphine LA m-Elson Hospira Konsyl-D Naphcon Forte Naltraccord AstraZeneca Habitrol Habitrol Habitrol Apo-Nicotinic Acid Arrow-Norfloxacin Primolut N28 Nilstat Nilstat Nilstat 2014 2014 2014 2014 2013 2013 2013 2014 2013 2014 2014 2013 2015 2014 2014 2013 2014 2013 2013 2014 2014 2014

2013

Morphine tartrate Mucilaginous laxatives Naphazoline hydrochloride Naltrexone hydrochloride Neostigmine Nicotine

Inj 80 mg per ml, 1.5 ml & 5 ml Dry Eye drops 0.1% Tab 50 mg Inj 2.5 mg per ml, 1 ml Gum 2 mg & 4 mg (classic, fruit, mint) Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Tab 50 mg & 500 mg Tab 400 mg Tab 5 mg Oral liq 100,000 u per ml Cap 500,000 u Tab 500,000 u

Nicotinic acid Norfloxacin Norethisterone Nystatin

Sole Subsidised Supply Products – cumulative to July 2012

Generic Name

Omeprazole

Presentation

Cap 10 mg, 20 mg & 40 mg Powder Inj 40 mg Tab disp 4 mg & 8 mg Tab 4 mg & 8 mg

Brand Name Expiry Date*

Omezol Relief Midwest Dr Reddy’s Omeprazole Dr Reddy’s Ondansetron Dr Reddy’s Ondansetron Ox-Pam Pantocid IV Dr Reddy’s Pantoprazole Parafast Ethics Paracetamol Paracare Double Strength Paracetamol + Codeine (Relieve) Lacri-Lube Loxamine Breath-Alert Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax Lyderm A-Scabies DBL Pethidine Hydrochloride DBL Pethidine Hydrochloride Cilicaine VK AFT AFT Coloxyl Dr Reddy’s Pramipexole 2014 2013 2014

Ondansetron

2013

Oxazepam Pantoprazole

Tab 10 mg & 15 mg Inj 40 mg Tab 20 mg & 40 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Eye oint with soft white paraffin Tab 20 mg Low range & normal range Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Tab 0.25 mg & 1 mg Crm 5% Lotn 5% Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml

2014 2014 2013 2014

Paracetamol

Paracetamol with codeine Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak flow meter Pegylated interferon alpha-2A

2014 2013 2013 2015 31/12/12

Pergolide Permethrin Pethidine hydrochloride

2014 2014 2014

Phenoxymethylpenicillin (Pencillin V)

Cap potassium salt 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Oral drops 10% Tab 0.125 mg & 0.25 mg

2013

Poloxamer Pramipexole hydrochloride

Sole Subsidised Supply Products – cumulative to July 2012

Generic Name

Pravastatin Procaine penicillin Pyridostigmine bromide Pyridoxine hydrochloride Ranitidine hydrochloride Rifabutin Ropinirole hydrochloride Sertraline Simvastatin

Presentation

Tab 20 mg & 40 mg Inj 1.5 mega u Tab 60 mg Tab 25 mg Tab 50 mg Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg Cap 150 mg Tab 0.25 mg, 1 mg, 2 mg & 5 mg Tab 50 mg & 100 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Inj 23.4%, 20 ml Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Grans effervescent 4 g sachets Eye drops 2% Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) 800 ml 230 ml (single patient) Tab 25 mg & 100 mg Inj 12 mg per ml, 0.5 ml Tab 50 mg & 100 mg Tab 20 mg Cap 400 µg Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml & 1,000 ml Tab 10 mg Cap 5 mg, 20 mg, 100 mg & 250 mg Tab 1 mg, 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 µg Inj 1 mg per ml, 1 ml

Brand Name Expiry Date*

Cholvastin Cilicaine Mestinon PyridoxADE Apo-Pyridoxine Peptisoothe Arrow-Ranitidine Mycobutin Ropin Arrow-Sertraline Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg Biomed Micolette Ural Rexacrom Genotropin Genotropin Volumatic Space Chamber Plus Spirotone Arrow-Sumatriptan Arrow-Sumatriptan Genox Tamsulosin-Rex Pinetarsol 2014 2014 2014 2014 2014 2013 2013 2013 2014

Sodium chloride Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium cromoglycate Somatropin Spacer device

2013 2013 2013 2013 31/12/12 2015

Spironolactone Sumatriptan Tamoxifen citrate Tamsulosin hydrochloride Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Temozolomide Terazosin hydrochloride Terbinafine Testosterone cypionate Tetracosactrin

2013 2013 2014 2013 2014

Normison Temaccord Arrow Dr Reddy’s Terbinafine Depo-Testosterone Synacthen Synacthen Depot

2014 2013 2013 2014 2014 2014

Sole Subsidised Supply Products – cumulative to July 2012

Generic Name

Timolol maleate Tobramycin

Presentation

Eye drops 0.25% & 0.5% Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 2 ml Tab 100 mg Cap 50 mg Inj 10 mg per ml, 1 ml Inj 40 mg per ml, 1 ml Crm 0.02% Oint 0.02% 0.1% in Dental Paste USP Tab 500 mg Eye drops 0.5% & 1% Eye drops 0.25% Inj 500 mg Tab 40 mg & 80 mg Tab, strong, BPC Tab (BPC cap strength) Cap 100 mg Oral liq 10 mg per ml Caps 137.4 mg (50 mg elemental) Tab 7.5 mg

Brand Name Expiry Date*

Arrow-Timolol Tobrex Tobrex DBL Tobramycin Tasmar Arrow-Tramadol Kenacort-A Kenacort-A40 Aristocort Aristocort Oracort Cyklokapron Mydriacyl Enuclene Mylan Isoptin B-PlexADE MultiADE Retrovir Retrovir Zincaps Apo-Zopiclone 2014 2014

Tolcapone Tramadol hydrochloride Triamcinolone acetonide

2014 2014 2014

Tranexamic acid Tropicamide Tyloxapol Vancomycin hydrochloride Verapamil hydrochloride Vitamin B complex Vitamins Zidovudine [AZT] Zinc sulphate Zopiclone July changes in bold

2013 2014 2014 2014 2014 2013 2013 2013 2014 2014

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 July 2012

30 53 69 96 INSULIN ASPART s Inj 100 iu per ml, 3 ml prefilled pen ......................................... 52.15 FELODIPINE ❋ Tab long-acting 5 mg ................................................................ 3.10 ❋ Tab long-acting 10 mg .............................................................. 4.60 ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab 20 µg with levonorgestrel 100 µg and 7 inert tab – Up to 84 tab available on a PSO .......................................... 2.95 5 30 30 ✔ NovoMix 30 FlexPen ✔ Plendil ER ✔ Plendil ER

✔ Ava 20 ED

BACILLUS CALMETTE-GUERIN VACCINE – Hospital pharmacy [Xpharm] Inj multi-dose vial (10 dose) 0.5 ml ........................................... 0.00 1 ✔ BCG Vaccine For infants at increased risk of tuberculosis. Increased risk is defined as: 1) living in a house or family with a person with current or past history of TB or 2) have one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer or 3) during their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000 Note a list of countries with high rates of TB are available at www.moh.govt.nz/immunisation or www.bcgatlas.org/index.php DIPTHERIA AND TETANUS VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 For adults aged 45 and 65 years old. 1 ✔ ADT Booster

DIPTHERIA, TETANUS, AND PERTUSSIS VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 1 For children aged 11 years old.

✔ Boostrix

DIPTHERIA, TETANUS, PERTUSSIS, AND POLIO VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 1 ✔ Infanrix-IPV For children aged 4 years old. DIPTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B, AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 1 ✔ Infanrix-hexa For children aged 6 weeks, 3 months, and 5 months old. HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 1 ✔ Act-HIB For children aged 15 months old, children aged 0-16 years with functional asplenia, or for patients pre- and post-splenectomy. HUMAN PAPILLOMAVIRUS VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 1 ✔ Gardasil Three doses over a period of six months for young women aged between 12 and 19 years old. HEPATITIS B VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 For household or sexual contacts of known hepatitis B carriers. 1 ✔ HBvaxPro

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 July 2012 (continued)

96 MEASLES, MUMPS AND RUBELLA VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 1 ✔ M-M-R II For children aged 15 months and 4 years old or for any individual susceptible to measles, mumps or rubella. MENINGOCOCCAL A, C, Y AND W-135 VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 1 ✔ Menomune For patients pre-and post-splenectomy or children aged 0-16 years with functional asplenia. PNEUMOCOCCAL (PCV13) VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 For high risk children under the age of 5 PNEUMOCOCCAL VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 For children aged 6 weeks, 3 months, 5 months, and 15 months old. 1 ✔ Prevenar 13

✔ Synflorix

PNEUMOCOCCAL POLYSACCHARIDE VACCINE – Hospital pharmacy [Xpharm] Inj 0.5 ml................................................................................... 0.00 1 ✔ Pneumovax 23 For patients pre-and post-splenectomy or children aged 0-16 years with functional asplenia. BUPRENORPHINE WITH NALOXONE – Special Authority see SA1203 – Retail pharmacy a) Only on a controlled drug form b) No patient co-payment payable Tab sublingual 2 mg with naloxone 0.5 mg .............................. 57.40 28 ✔ Suboxone Tab sublingual 8 mg with naloxone 2 mg .............................. 166.00 28 ✔ Suboxone ➽ SA1203 Special Authority for Subsidy Initial application - (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria: All of the following: 1 Patient is opioid dependent; and 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and 3 Applicant works in an opioid treatment service approved by the Ministry of Health. Initial application - (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 Patient is opioid dependent; and 2 Patient will not be receiving methadone; and 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and 4 Applicant works in an opioid treatment service approved by the Ministry of Health. Renewal – (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria: All of the following: 1 Patient is opioid dependent; and 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back into opioid use and another attempt is planned; and 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and 4 Applicant works in an opioid treatment service approved by the Ministry of Health. Renewal - (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following: continued... ❋ Three months or six months, as applicable, dispensed all-at-once

138

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 July 2012 (continued)

continued... 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient. Renewal - (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 Patient received but failed detoxification with buprenorphine with naloxone; and 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Effective 1 June 2012

31 SODIUM NITROPRUSSIDE – Maximum of 50 strip per prescription Test strip – Not on a BSO .......................................................... 6.00 50 strip OP ✔ Accu-Chek KeturTest

AZITHROMYCIN Grans for oral liq 200 mg per 5 ml - Subsidy by endorsement ................................................................... 13.20 15 ml ✔ Zithromax a) Maximum of 5 days per prescription where the patient is less than one year old; and b) Patient has pertussis and this has been notified to the Medical Officer of Health; or c) Patient has had direct contact with a notified case of pertussis and requires prophylaxis; d) And the prescription is endorsed accordingly (note treatment and prophylaxis of pertussis are unapproved indications) AURANOFIN Tab 3 mg ............................................................................... 68.99 OXALIPLATIN – PCT only – Specialist – Special Authority see SA0900 Inj 50 mg ................................................................................ 15.32 Inj 100 mg .............................................................................. 25.01 60 1 1 ✔ Ridaura S29 S29 ✔ Oxaliplatin Actavis 50 ✔ Oxaliplatin Actavis 100 ✔ DBL Epirubicin Hydrochloride ✔ DBL Epirubicin Hydrochloride ✔ DBL Epirubicin Hydrochloride

98 140

147

EPIRUBICIN – PCT only – Specialist Inj 2 mg per ml, 25 ml ............................................................. 39.38 Inj 2 mg per ml, 50 ml ............................................................ 58.20 Inj 2 mg per ml, 100 ml .......................................................... 94.50

1 1 1

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings – effective 1 May 2012

51 BISOPROLOL FUMARATE Tab 2.5 mg ............................................................................... 3.88 Tab 5 mg .................................................................................. 4.74 Tab 10 mg ................................................................................ 9.18 PROPYLTHIOURACIL – Special Authority see SA1199 – Retail Pharmacy Tab 50 mg .............................................................................. 35.00 30 30 30 100 ✔ Bosvate ✔ Bosvate ✔ Bosvate ✔ PTU S29

➽ SA1199 Special Authority for Subsidy Initial application only from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The patient has hyperthyroidism; and 2 The patient is intolerant of carbimazole or carbimazole is contraindicated. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment. 170 BRIMONIDINE TARTRATE ❋ Eye Drops 0.2%......................................................................... 6.45 5 ml OP ✔ Arrow-Brimonidine

New Listings – effective 13 April 2012

140 CARBOPLATIN – PCT only – Specialist Inj 10 mg per ml, 45 ml ........................................................... 50.00 1 ✔ DBL Carboplatin

Effective 1 April 2012

147 164 DOXORUBICIN – PCT only – Specialist Inj 50 mg ............................................................................... 40.00 SALBUTAMOL ‡ Oral liq 2 mg per 5 ml ............................................................. 1.99 1 150 ml ✔ DBL Doxorubicin ✔ Ventolin

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 July 2012

43 DABIGATRAN Dabigatran will not be funded Close Control in amounts less than 4 weeks of treatment. Cap 75 mg – No more than 2 cap per day .............................. 148.00 60 OP Cap 110 mg .......................................................................... 148.00 60 60 OP Cap 150 mg ......................................................................... 148.00 60 OP 60 FELODIPINE ❋ Tab long-acting 2.5 mg – No more than 1 tab per day ................ 2.90 30 ✔ Pradaxa ✔ Pradaxa ✔ Pradaxa ✔ Pradaxa ✔ Pradaxa ✔ Plendil ER

53 139

NICOTINE Nicotine will not be funded Close Control under the dispensing frequency rule in amounts less than 4 weeks of treatment. Patch 7 mg – Up to 28 patch available on a PSO ..................... 18.13 28 ✔ Habitrol Patch 14 mg – Up to 28 patch available on a PSO ................... 18.81 28 ✔ Habitrol Patch 21 mg – Up to 28 patch available on a PSO ................... 19.14 28 ✔ Habitrol Lozenge 1 mg – Up to 216 loz available on a PSO .................... 19.94 216 ✔ Habitrol Lozenge 2 mg – Up to 216 loz available on a PSO .................... 24.27 216 ✔ Habitrol Gum 2 mg (Classic) – Up to 384 piece available on a PSO ....... 36.47 384 ✔ Habitrol Gum 2 mg (Fruit) – Up to 384 piece available on a PSO ........... 36.47 384 ✔ Habitrol Gum 2 mg (Mint) – Up to 384 piece available on a PSO ........... 36.47 384 ✔ Habitrol Gum 4 mg (Classic) – Up to 384 piece available on a PSO ....... 42.04 384 ✔ Habitrol Gum 4 mg (Fruit) – Up to 384 piece available on a PSO ........... 42.04 384 ✔ Habitrol Gum 4 mg (Mint) – Up to 384 piece available on a PSO ........... 42.04 384 ✔ Habitrol VARENICLINE TARTRATE – Special Authority see SA1161 – Retail pharmacy a) Varenicline will not be funded Close Control under the dispensing frequency rule in amounts less than 2 weeks of treatment. b) A maximum of 3 months’ varenicline will be subsidised on each Special Authority approval. Tab 1 mg ................................................................................ 67.74 28 ✔ Champix 135.48 56 ✔ Champix Tab 0.5 mg × 11 and 1 mg × 14 .......................................... 60.48 25 OP ✔ Champix PREMATURE BIRTH FORMULA – Special Authority see SA12211109 – Hospital pharmacy [HP3] Liquid ........................................................................................ 0.75 100 ml OP ✔ S26LBW Gold RTF ➽ SA12211109 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months where the patient is infant weighing less than 1.5 kg at birth. Note: Subsidy for patients approved prior to 1 July 2012. Approvals valid for 6 months. No new approvals will be granted from 1 July 2012.

139

199

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2012 (continued)

199 AMINO ACID FORMULA – Special Authority see SA12191111– Hospital pharmacy [HP3] Powder .................................................................................... 6.00 48.5 g OP ✔ Vivonex Pediatric 56.00 400 g OP ✔ Neocate ✔ Neocate LCP Powder (tropical) .................................................................... 56.00 400 g OP ✔ Neocate Advance Powder (unflavoured) ............................................................. 53.00 400 g OP ✔ Elecare ✔ Elecare LCP 56.00 ✔ Neocate Advance ✔ Neocate Gold Powder (vanilla) ...................................................................... 53.00 400 g OP ✔ Elecare ➽ SA12191111 Special Authority for Subsidy Initial application — (Transition from Old Form (SA0603)) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient is currently receiving funded amino acid formula under Special Authority form SA0603; and 2 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and 3 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and 4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted. Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following: 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or 2 History of anaphylaxis to cows milk protein formula or dairy products; or 3 Eosinophilic oesophagitis. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. 200 EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA12201112 – Hospital pharmacy [HP3] Powder ................................................................................... 15.21 450 g OP ✔ Pepti Junior Gold ➽ SA12201112 Special Authority for Subsidy Initial application — (Transition from Old Form (SA0603)) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 All of the following: 1.1 The infant is currently receiving funded amino acid formula under Special Authority form SA0603; and 1.2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

continued... ❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2012 (continued)

continued... 1.3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted; or 2 All of the following: 2.1 The patient is currently receiving funded extensively hydrolysed formula under Special Authority form SA0603; and 2.2 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and 2.3 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and 2.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and 1.2 Either: 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or 2 Severe malabsorption; or 3 Short bowel syndrome; or 4 Intractable diarrhea; or 5 Biliary atresia; or 6 Cholestatic liver diseases causing malsorption; or 7 Chylous ascite; or 8 Chylothorax; or 9 Cystic fibrosis; or 10 Proven fat malabsorption; or 11 Severe intestinal motility disorders causing significant malabsorption; or 12 Intestinal failure. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. Renewal —(Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The infant is currently receiving funded amino acid formula; and 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2012

26 31 ALUMINIUM HYDROXIDE (addition of stat dispensing) ❋ Tab 600 mg .......................................................................... 12.56 100 ✔ Alu-Tab

❋ Tab 15 mg .............................................................................. 2.61 ❋ Tab 30 mg .............................................................................. 5.23 ❋ Tab 45 mg .............................................................................. 7.80 ❋ Cap 0.25 µg ......................................................................... 26.32 ❋ Cap 1 µg .............................................................................. 87.98 ❋ Oral drops 2 µg per ml .......................................................... 60.68 ❋ Powder ................................................................................. 72.00 ❋ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg

SODIUM FLUORIDE (addition of stat dispensing) VITAMIN A WITH VITAMINS D AND C (addition of stat dispensing) per 10 drops ......................................................................... 4.50 ALFACALCIDOL (addition of stat dispensing)

PIOGLITAZONE – Special Authority see SA0959 – Retail pharmacy (addition of stat dispensing) 28 ✔ Pizaccord 28 ✔ Pizaccord 28 ✔ Pizaccord 100 100 20 ml OP ✔ One-Alpha ✔ One-Alpha ✔ One-Alpha

37 37

MULTIVITAMINS – Special Authority see SA1036 – Retail pharmacy (addition of stat dispensing) 200 g OP ✔ Paediatric Seravit

10 ml OP 100 90 100

✔ Vitadol C ✔ PSM

❋ Tab 1.1 mg (0.5 mg elemental) ............................................... 5.00 ❋ Tab 256 µg (150 µg elemental iodine) ..................................... 7.55 ❋ Tab 200 mg (65 mg elemental) ............................................... 4.35 ❋ Tab 310 mg (100 mg elemental) with folic acid

IRON POLYMALTOSE (addition of stat dispensing) FERROUS FUMARATE WITH FOLIC ACID (addition of stat dispensing) 350 µg .................................................................................. 4.75 FERROUS FUMARATE (addition of stat dispensing) POTASSIUM IODATE (addition of stat dispensing)

38 38 38

✔ NeuroKare ✔ Ferro-tab

60 5 10

✔ Ferro-F-Tabs ✔ Ferrum H ✔ Mayne

❋ Inj 50 mg per ml, 2 ml ........................................................... 19.90 ❋ Inj 49.3%, 5 ml

MAGNESIUM SULPHATE (addition of stat dispensing) ..................................................................... 26.60 CLOPIDOGREL (addition of stat dispensing) ❋ Tab 75 mg – For clopidogrel oral liquid formulation refer, page 175 ............................................................................ 16.25

39 41

✔ Apo-Clopidogrel

PRASUGREL – Special Authority see SA12011194 – Retail pharmacy Tab 5 mg ............................................................................. 108.00 28 ✔ Effient Tab 10 mg ........................................................................... 120.00 28 ✔ Effient ➽ SA12011194 Special Authority for Subsidy Initial application - (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*. continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2012 (continued)

continued... Initial application - (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*. Initial application – (stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has experienced cardiac stent thrombosis whilst on clopidogrel. Renewal - (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*. Renewal - (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*. Note: *Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in nonasthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment. 45 GEMFIBROZIL (addition of stat dispensing)

❋ Tab 600 mg .......................................................................... 14.00 ❋ Tab 20 mg .............................................................................. 5.44 ❋ Tab 40 mg .............................................................................. 9.28 ❋ Tab 6.25 mg ......................................................................... 21.00 ❋ Tab 12.5 mg ......................................................................... 27.00 ❋ Tab 25 mg – For carvedilol oral liquid formulation refer,

page 175 ............................................................................ 33.75 ISRADIPINE (addition of stat dispensing) CARVEDILOL (addition of stat dispensing) PRAVASTATIN – See prescribing guideline (addition of stat dispensing)

60 30 30 30 30 30 30 30 500 g

✔ Lipazil ✔ Cholvastin ✔ Cholvastin ✔ Dilatrend ✔ Dilatrend ✔ Dilatrend ✔ Dynacirc-SRO ✔ Dynacirc-SRO ✔ Multichem PSM

❋ Cap long-acting 2.5 mg ........................................................... 7.50 ❋ Cap long-acting 5 mg .............................................................. 7.85 ❋ Oint BP

ZINC AND CASTOR OIL (addition of stat dispensing) ................................................................................... 3.83 (5.11)

ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab 30 µg with levonorgestrel 150 µg and 7 inert tab................. 2.45 (6.62)

✔ Ava 30 ED Levlen ED Monofeme (14.49) Nordette 28 (16.50) Microgynon 30 ED a) Higher subsidy of up to $15.00 per 84 tab with Special Authority see SA0500 on the preceding page b) Up to 84 tab available on a PSO

❋ Tab 5 mg ................................................................................ 5.10 ❋ Cap 400 µg

FINASTERIDE – Special Authority see SA0928 – Retail pharmacy (addition of stat dispensing) 30 ✔ Rex Medical TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 – Retail pharmacy (addition of stat dispensing) ............................................................................ 5.98 30 ✔ Tamsulosin-Rex

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2012 (continued)

❋ Tab 250 mg – For terbinafine oral liquid formulation refer,

page 175 .............................................................................. 1.78 14 ✔ Dr Reddy’s Terbinafine

TERBINAFINE (addition of stat dispensing)

❋ Tab 7.5 mg ........................................................................... 11.50 ❋ Tab 70 mg ............................................................................ 22.90

MELOXICAM – Special Authority see SA1034 – Retail pharmacy (addition of stat dispensing) 30 ✔ Arrow-Meloxicam ALENDRONATE SODIUM – Special Authority see SA1039 – Retail pharmacy (addition of stat dispensing) 4 ✔ Fosamax

109 109

109

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA1039 – Retail pharmacy (addition of stat dispensing) ❋ Tab 70 mg with cholecalciferol 5,600 iu ................................ 22.90 4 ✔ Fosamax Plus

❋ Tab 40 mg .......................................................................... 133.00

ALENDRONATE SODIUM – Special Authority see SA0949 – Retail pharmacy (addition of stat dispensing) 30 ✔ Fosamax RALOXIFENE HYDROCHLORIDE – Special Authority see SA1138 – Retail pharmacy (addition of stat dispensing) 28 ✔ Evista

110 119

❋ Tab 60 mg ............................................................................ 53.76

119

MOCLOBEMIDE (addition of stat dispensing) Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide. ❋ Tab 150 mg .......................................................................... 69.23 500 ✔ Apo-Moclobemide ❋ Tab 300 mg .......................................................................... 31.33 100 ✔ Apo-Moclobemide

❋ Tab 15 mg ............................................................................ 95.00 ❋ Tab 10 mg ............................................................................ 22.94 ❋ Tab 10 mg .............................................................................. 2.65 ❋ Tab 20 mg .............................................................................. 4.20 ❋ Tab 20 mg .............................................................................. 2.38 ❋ Tab 50 mg .............................................................................. 5.40 ❋ Tab 100 mg ............................................................................ 9.60

SERTRALINE (addition of stat dispensing) PAROXETINE HYDROCHLORIDE (addition of stat dispensing) ESCITALOPRAM (addition of stat dispensing) TRANYLCYPROMINE SULPHATE (addition of stat dispensing)

PHENELZINE SULPHATE (addition of stat dispensing)

100 50 28 28 30 90 90

✔ Nardil ✔ Parnate ✔ Loxalate ✔ Loxalate ✔ Loxamine ✔ Arrow-Sertraline ✔ Arrow-Sertraline

119 120

120 120

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2012 (continued)

126

❋ Tab 4 mg ................................................................................ 5.10 ❋ Tab disp 4 mg ......................................................................... 1.70 ❋ Tab 8 mg ................................................................................ 1.70 ❋ Tab disp 8 mg ......................................................................... 2.00

ANASTROZOLE (addition of stat dispensing)

ONDANSETRON (addition of stat dispensing)

30 10 10 10

✔ Dr Reddy’s Ondansetron ✔ Dr Reddy’s Ondansetron ✔ Dr Reddy’s Ondansetron ✔ Dr Reddy’s Ondansetron ✔ Aremed ✔ Arimidex ✔ DP-Anastrozole ✔ Aromasin ✔ Letara

155

❋ Tab 1 mg .............................................................................. 26.55

30 30 30

155

❋

EXEMESTANE (addition of stat dispensing) Tab 25 mg .......................................................................... 22.57 LETROZOLE (addition of stat dispensing)

155

❋ Tab 2.5 mg ........................................................................... 26.55

Effective 1 May 2012

44 SODIUM CHLORIDE Not funded for use as a nasal drop. Only funded for nebuliser use when in conjunction with an antibiotic intended for nebuliser use. Inj 23.4%, 20 ml - For sodium chloride oral liquid formulation refer, page 178 ................................................ 31.25 5 ✔ Biomed CICLOPIROXOLAMINE CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail soln 8% .......................................................................... 19.85 Soln 1% .................................................................................... 4.36 (11.54)

3 g OP 20 ml OP

✔ Batrafen Batrafen

143

GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1087 Inj 1 g ..................................................................................... 62.50 1 ✔ Gemcitabine Actavis Inj 200 mg .............................................................................. 12.50 1 1000 S29 ✔ Gemcitabine Actavis 200 S29

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 May 2012 (continued)

152 SUNITINIB – Special Authority see SA1200 1162 – Retail pharmacy Cap 12.5 mg ..................................................................... 2,315.38 Cap 25 mg ......................................................................... 4,630.77 Cap 50 mg ......................................................................... 9,261.54 28 28 28 ✔ Sutent ✔ Sutent ✔ Sutent

➽ SA1200 1162 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 The patient has metastatic renal cell carcinoma; and 2 Either Any of the following: 2.1 The patient is sunitinib treatment naive; or 2.2 The patient received sunitinib prior to 1 November 2010 and disease has not progressed; and The patient has only received prior cytokine treatment; or 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or 2.4 Both 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and 2.4.2 The cancer did not progress whilst on pazopanib; and 3 The patient has good performance status (WHO/ECOG grade 0-2); and 4 The disease is of predominant clear cell histology; and 5 The patient has intermediate or poor prognosis defined as : Any of the following: 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or 5.2 Haemoglobin level < lower limit of normal; or 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L) ; or 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or 5.5 Karnofsky performance score of ≤ 70; or 5.6 ≥ 2 sites of organ metastasis; and 6 Sunitinib to be used for a maximum of 2 cycles. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 No evidence of disease progression; and 2 The treatment remains appropriate and the patient is benefiting from treatment. Notes: Sunitinib treatment should be stopped if disease progresses. Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6 156 Immune Modulators Protein-Tyrosine Kinase Inhibitors LAPATINIB DITOSYLATE – Special Authority see SA1191 – Retail pharmacy Tab 250 mg ...................................................................... 1,899.00 170 70 ✔ Tykerb

Glaucoma Preparations - Carbonic Anhydrase Inhibitors Prescribing Guidelines Trusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); and 2) those trials have indicated that that person does not respond adequately to treatment with those other agents.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 May 2012 (continued)

170 ACETAZOLAMIDE ❋ Tab 250 mg – For acetazolamide oral liquid formulation refer, page 175 ............................................................................ 17.03 BRINZOLAMIDE (change to stat dispensing) s ❋ Eye Drops 1% ..................................................................... 9.77 DORZOLAMIDE HYDROCHLORIDE ❋ Eye drops 2% ........................................................................... 9.77 (13.95) DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE ❋ Eye drops 2% with timolol maleate 0.5% ................................. 15.50

100 5 ml OP 5 ml OP

✔ Diamox ✔ Azopt

Trusopt 5 ml OP ✔ Cosopt

Glaucoma Preparations - Prostaglandin Analogues Prescribing Guideline Bimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure. Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: 1) That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and 2) Those trials have indicated that that person does not respond adequately to treatment with those other agents. BIMATOPROST – Retail pharmacy-Specialist (change to stat dispensing) See prescribing guideline above s ❋ Eye drops 0.03% ............................................................... 18.50 LATANOPROST – Retail pharmacy-Specialist (change to stat dispensing) See prescribing guideline above s ❋ Eye drops 50 µg per ml, 2.5 ml ........................................... 9.75 TRAVOPROST – Retail pharmacy-Specialist (change to stat dispensing) See prescribing guideline above s ❋ Eye drops 0.004% ............................................................ 19.50 Glaucoma Preparations - Other BRIMONIDINE TARTRATE – See prescribing guideline below ❋ Eye Drops 0.2% ........................................................................ 6.45 7.93

170

3 ml OP

✔ Lumigan

2.5 ml OP ✔ Hysite

170

2.5 ml OP ✔ Travatan

5 ml OP

✔ Arrow-Brimonidine ✔ AFT

Prescribing Guidelines Brimonidine tartrate is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Brimonidine tartrate should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless: • that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and • those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 May 2012 (continued)

171 BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE – See prescribing guideline below (change to stat dispensing) s ❋ Eye drops 0.2% with timolol maleate 0.5% ......................... 18.50 5 ml OP ✔ Combigan Prescribing Guidelines Combigan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Combigan should only be prescribed when: 1) less expensive first line agents for the treatment of glaucoma are contraindicated; or 2) the response to such subsidised agents is inadequate; or 3) the patient cannot tolerate such subsidised agents. 178 Standard Formulae SODIUM CHLORIDE ORAL LIQUID Sodium chloride inj 23.4%, 20ml qs Water qs (Only funded if prescribed for treatment of hyponatraemia)

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 July 2012

27 29 31 MESALAZINE ( subsidy) Enema 1 g per 100 ml ............................................................. 44.12 GLUCAGON HYDROCHLORIDE ( subsidy) Inj 1 mg syringe kit - up to 5 kit available on a PSO .................. 32.00 7 1 ✔ Pentasa ✔ Glucagen Hypokit ✔ Pizaccord ✔ Pizaccord ✔ Pizaccord ✔ ABM Hydroxocobalamin ✔ Clexane ✔ Clexane ✔ Clexane ✔ Clexane ✔ Clexane ✔ Clexane ✔ Clexane

PIOGLITAZONE – Special Authority see SA0959 – Retail pharmacy ( subsidy) ❋ Tab 15 mg ............................................................................... 1.50 28 ❋ Tab 30 mg ................................................................................ 2.50 28 ❋ Tab 45 mg ............................................................................... 3.50 28 HYDROXOCOBALAMIN ( subsidy) ❋ Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO ................ 5.10 3

37 42

ENOXAPARIN SODIUM – Special Authority see SA1174 – Retail pharmacy ( subsidy) Inj 20 mg ................................................................................ 37.24 10 Inj 40 mg ................................................................................ 49.69 10 Inj 60 mg ................................................................................ 74.91 10 Inj 80 mg ............................................................................... 99.86 10 Inj 100 mg ........................................................................... 125.06 10 Inj 120 mg ........................................................................... 155.40 10 Inj 150 mg ........................................................................... 177.60 10 METOPROLOL SUCCINATE ( price) ❋ Tab long-acting 23.75 mg ......................................................... 0.96 (7.50) ❋ Tab long-acting 47.5 mg ........................................................... 1.41 (7.50) ❋ Tab long-acting 95 mg .............................................................. 2.42 (7.50) METOPROLOL SUCCINATE ( price) ❋ Tab long-acting 190 mg ............................................................ 4.66 (7.50) FELODIPINE ( subsidy) ❋ Tab long-acting 2.5 mg ............................................................ 2.90 FUROSEMIDE ( subsidy) ❋ Tab 40 mg – Up to 30 tab available on a PSO .......................... 10.25 CROTAMITON ( subsidy) a) Only on a prescription b) Not in combination Crm 10%. .................................................................................. 3.48 30

Betaloc CR 30 Betaloc CR 30 Betaloc CR 30 Betaloc CR 30 1,000 ✔ Plendil ER ✔ Diurin 40

53 54 59

20 g OP

✔ Itch-Soothe

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price – effective 1 July 2012 (continued)

61 MOMETASONE FUROATE ( subsidy) Crm 0.1% .................................................................................. 1.78 3.42 Oint 0.1% .................................................................................. 1.78 3.42 ACITRETIN – Special Authority see SA0954 – Retail pharmacy ( subsidy) Cap 10 mg .............................................................................. 35.95 Cap 25 mg ............................................................................. 85.40 NORETHISTERONE ( subsidy) ❋ Tab 350 µg – Up to 84 tab available on a PSO ........................... 6.00 CABERGOLINE ( subsidy) Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA1031................................ 6.25 25.00 ROXITHROMYCIN ( subsidy) Tab 150 mg ............................................................................. 7.48 Tab 300 mg ............................................................................ 14.40 83 FLUCLOXACILLIN SODIUM ( subsidy) Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO ............................................................................... 2.49 Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO ............................................................................... 3.25 15 g OP 45 g OP 15 g OP 45 g OP 100 100 84 ✔ m-Mometasone ✔ m-Mometasone ✔ m-Mometasone ✔ m-Mometasone ✔ Neotigason ✔ Neotigason ✔ Noriday 28

70 78

2 8 50 50

✔ Dostinex ✔ Dostinex ✔ ArrowRoxithromycin ✔ ArrowRoxithromycin

100 ml 100 ml

✔ AFT ✔ AFT

GENTAMICIN SULPHATE ( subsidy) Inj 40 mg per ml, 2 ml – Subsidy by endorsement .................... 6.50 10 ✔ Pfizer Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis and the prescription is endorsed accordingly. ETIDRONATE DISODIUM – See prescribing guideline ( subsidy) ❋ Tab 200 mg ............................................................................ 15.80 FENTANYL CITRATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml ................................................................ 4.50 Inj 50 µg per ml, 10 ml ............................................................ 11.77 100 ✔ Arrow-Etidronate

109 117

10 10

✔ Boucher and Muir ✔ Boucher and Muir

117

METHADONE HYDROCHLORIDE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets). ‡ Oral liq 2 mg per ml .................................................................. 5.55 200 ml ✔ Biodone ‡ Oral liq 10 mg per ml ................................................................ 6.55 200 ml ✔ Biodone Extra Forte

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price – effective 1 July 2012 (continued)

120 MIRTAZAPINE – Special Authority see SA0994 – Retail pharmacy ( subsidy) Tab 30 mg ................................................................................ 8.78 30 Tab 45 mg .............................................................................. 13.95 30 VENLAFAXINE – Special Authority see SA1061 – Retail pharmacy ( subsidy) Tab 37.5 mg .......................................................................... 12.67 28 Tab 75 mg .............................................................................. 19.00 Tab 150 mg ............................................................................ 23.41 Cap 37.5 mg .......................................................................... 15.84 Cap 75 mg ............................................................................. 31.67 Cap 150 mg ............................................................................ 38.82 125 128 CYCLIZINE HYDROCHLORIDE ( subsidy) Tab 50 mg ............................................................................... 0.59 LITHIUM CARBONATE ( subsidy) Tab 250 mg ........................................................................... 34.30 Tab 400 mg ............................................................................ 12.83 QUETIAPINE ( subsidy) Tab 25 mg .............................................................................. 10.50 Tab 100 mg ............................................................................ 21.00 Tab 200 mg ............................................................................ 36.00 Tab 300 mg ............................................................................ 60.00 RISPERIDONE ( subsidy) Tab 0.5 mg ............................................................................... 1.17 (2.86) Tab 1 mg .................................................................................. 6.00 (16.92) Tab 2 mg ................................................................................ 11.00 (33.84) Tab 3 mg ................................................................................ 15.00 (50.78) Tab 4 mg ................................................................................ 20.00 (67.68) Oral liq 1 mg per ml ................................................................. 18.35 (25.26) IDARUBICIN HYDROCHLORIDE – PCT only – Specialist ( subsidy) Inj 5 mg ............................................................................... 100.00 Inj 10 mg ............................................................................. 200.00 Inj 1 mg for ECP ...................................................................... 22.20 28 28 28 28 28 10 500 100 90 90 90 90 20 Risperdal 60 Risperdal 60 Risperdal 60 Risperdal 60 Risperdal 30 ml Risperdal 1 1 1 mg ✔ Zavedos ✔ Zavedos ✔ Baxter ✔ Navelbine ✔ Navelbine ✔ Baxter ✔ Avanza ✔ Avanza ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Efexor XR ✔ Efexor XR ✔ Efexor XR ✔ Nausicalm ✔ Lithicarb FC ✔ Lithicarb FC ✔ Quetapel ✔ Quetapel ✔ Quetapel ✔ Quetapel

120

128

129

147

149

VINORELBINE – PCT only – Specialist – Special Authority see SA1013 ( subsidy) Inj 10 mg per ml, 1 ml ............................................................ 12.85 1 Inj 10 mg per ml, 5 ml ............................................................ 64.25 1 Inj 1 mg for ECP ....................................................................... 1.45 1 mg

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price – effective 1 July 2012 (continued)

162 163 PROMETHAZINE HYDROCHLORIDE ( subsidy) ❋ Tab 10 mg ................................................................................ 1.99 ❋ Tab 25 mg ................................................................................ 2.99 50 50 ✔ Allersoothe ✔ Allersoothe

EFORMOTEROL FUMARATE – See prescribing guideline ( subsidy) Note: Repeats for eformoterol fumarate will be fully subsidised where the initial dispensing is before 1 February 2012. Powder for inhalation, 6 µg per dose, breath activated ............ 10.32 60 dose OP (16.90) Oxis Turbuhaler Powder for inhalation, 12 µg per dose, and monodose device .......................................................... 20.64 60 dose (35.80) Foradil CHLORAMPHENICOL ( subsidy) Eye drops 0.5% ......................................................................... 1.20 LATANOPROST – Retail pharmacy-Specialist ( subsidy) ❋ Eye drops 50 µg per ml, 2.5 ml ................................................ 1.99 BRIMONIDINE TARTRATE ( subsidy) ❋ Eye Drops 0.2%......................................................................... 6.45 10 ml OP ✔ Chlorafast

168 170 170 193

2.5 ml OP ✔ Hysite 5 ml OP ✔ AFT

ORAL FEED (POWDER) – Special Authority see SA1104 – Hospital pharmacy [HP3] ( subsidy) Powder (chocolate) ................................................................ 13.00 900 g OP ✔ Ensure Powder (vanilla) ...................................................................... 13.00 900 g OP ✔ Ensure AMINO ACID FORMULA – Special Authority see SA1219 – Hospital pharmacy [HP3] ( subsidy) Powder (unflavoured) .............................................................. 53.00 400 g OP ✔ Elecare ✔ Elecare LCP Powder (vanilla) ...................................................................... 53.00 400 g OP ✔ Elecare

199

Effective 1 June 2012

52 69 METOPROLOL SUCCINATE ( subsidy) ❋ Tab long-acting 23.75 mg ........................................................ 0.96 (2.18) ❋ Tab long-acting 47.5 mg ......................................................... 1.41 (2.74) ❋ Tab long-acting 95 mg ............................................................ 2.42 (4.71) ❋ Tab long-acting 190 mg ............................................................ 4.66 (8.51) ETHINYLOESTRADIOL WITH LEVONORGESTREL ( subsidy) ❋ Tab 30 µg with levonorgestrel 150 µg and 7 inert tab – Up to 84 tab available on a PSO .......................................... 2.45 (6.62) (14.49) (16.50) 30 30 30 30 ✔ Myloc CR Betaloc CR ✔ Myloc CR Betaloc CR ✔ Myloc CR Betaloc CR ✔ Myloc CR Betaloc CR

84 Levlen ED Monofeme Nordette 28 Microgynon 30 ED

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price – effective 1 June 2012 (continued)

73 155 DEXAMETHASONE ( subsidy) ❋ Tab 1 mg – Retail pharmacy-Specialist ..................................... 5.87 Up to 30 tab available on a PSO ❋ Tab 4 mg – Retail pharmacy-Specialist ..................................... 8.16 Up to 30 tab available on a PSO 100 100 ✔ Douglas ✔ Douglas

MYCOPHENOLATE MOFETIL – Special Authority see SA1041 – Retail pharmacy ( subsidy) Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg ........................................................................... 60.00 50 ✔ Myaccord Cap 250 mg ........................................................................... 60.00 100 ✔ Myaccord

Effective 1 May 2012

33 URSODEOXYCHOLIC ACID – Special Authority see SA1188 – Retail pharmacy ( subsidy) Cap 300 mg – For ursodeoxycholic acid oral liquid formulation refer, page 75 ...................................................................... 71.50 100 ✔ Actigall METOPROLOL SUCCINATE ( subsidy) ❋ Tab long-acting 23.75 mg ......................................................... 0.96 ❋ Tab long-acting 47.5 mg .......................................................... 1.41 ❋ Tab long-acting 95 mg .............................................................. 2.42 ❋ Tab long-acting 190 mg ............................................................ 4.66 METOPROLOL TARTRATE ( subsidy) ❋ Tab 50 mg – For metoprolol tartrate oral liquid formulation refer, page 175 .................................................................... 16.00 ❋ Tab 100 mg ............................................................................ 21.00 ❋ Tab long-acting 200 mg ......................................................... 18.00 ❋ Inj 1 mg per ml, 5 ml .............................................................. 24.00 (34.00) ZINC AND CASTOR OIL ( subsidy) Oint BP ..................................................................................... 3.83 (5.11) CLINDAMYCIN ( subsidy) Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement - Retail pharmacy -Specialist ............................................................................ 9.90 RIZATRIPTAN ( subsidy) Tab orodispersible 10 mg ......................................................... 1.80 (17.56) DOMPERIDONE ( subsidy) ❋ Tab 10 mg – For domperidone oral liquid formulation refer, page 175 ................................................................... 11.99 30 30 30 30 ✔ Metoprolol - AFT CR ✔ Metoprolol - AFT CR ✔ Metoprolol - AFT CR ✔ Metoprolol - AFT CR

52 52 62

100 60 28 5

✔ Lopresor ✔ Lopresor ✔ Slow-Lopresor Betaloc

500 g PSM

16 3

✔ Dalacin C

125

Maxalt Melt

125

100

✔ Motilium

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturers Price – effective 1 May 2012 (continued)

154 OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA1016 – Retail pharmacy ( subsidy) Inj 50 µg per ml, 1 ml ............................................................. 19.24 5 (25.65) Hospira (43.50) Sandostatin Inj 100 µg per ml, 1 ml ............................................................ 36.38 5 (48.50) Hospira (81.00) Sandostatin Inj 500 µg per ml, 1 ml ......................................................... 131.25 5 (175.00) Hospira (399.00) Sandostatin DORNASE ALFA – Special Authority see SA0611– Retail pharmacy ( subsidy) Nebuliser soln, 2.5 mg per 2.5 ml ampoule ............................ 250.00 6 ACETYLCYSTEINE – Retail pharmacy-Specialist ( subsidy) Inj 200 mg per ml, 10 ml ...................................................... 178.00 10 ✔ Pulmozyme ✔ Martindale Acetylcysteine

164 179

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 July 2012

14 “Close Control” means dispensing: • in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or • in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of A), or B) or C) apply. • This Close Control rule defines patient groups or medicines which are eligible for more frequent dispensing periods and the conditions that must be met to enable any claim for payment for additional dispensing to be made. A) Frequency of dispensing for persons in residential care Pharmaceuticals can be dispensed in quantities of not less than 28 days to: • any person whose placement in a Residential Disability Care institution is funded by the Ministry of Health or a DHB; or • a person assessed as requiring long term residential care services and residing in an age related residential care facility; on the request of the person, their agent or caregiver or community residential service provider, provided the following conditions are met: i) the quantity or period of supply to be dispensed at any one time is not less than 28 days’ supply (except under conditions outlined in B.i below); and ii) the prescribing Practitioner or dispensing pharmacist has 1) included the name of the patient’s residential placement or facility on the prescription; and 2) included the patient’s NHI number on the prescription; and 3) specified the maximum quantity or period of supply to be dispensed at any one time. Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changedis able to have their medicine dispensed in accordance with B.i below. B) Flexible periods of supply for trial periods or safety The Schedule specifies for community patients a default length of dispensing (monthly/three monthly) for each pharmaceutical. Prescribers can request, and pharmacists may dispense, a higher frequency of dispensing in the following circumstances: If the prescribing Practitioner has met the prescribing conditions set out in B.iii below, and the pharmaceutical or patient fits within the provisions of B.i and B.ii below, a pharmacist may dispense more frequently than the Schedule default period of supply. i) Trial Periods The Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient’s first changed Prescription only); or ii) Safety 1) the Community Pharmaceutical is any of the following: a) a tri-cyclic antidepressant; or b) an antipsychotic; or c) a benzodiazepine; or d) a Class B Controlled Drug; or 2) The Community Pharmaceutical has been prescribed for a patient who: a) is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in clause A above; and b) in the opinion of the prescribing Practitioner, is intellectually impaired or frail, infirm or unable to manage their medicine without additional support. For B.i and B.ii all of the following conditions must be met: iii) The prescribing Practitioner has: 1) endorsed each Community Pharmaceutical on the Prescription clearly with the words “Close Control” or “CC”; and 2) initialled the endorsement in their own handwriting; and continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules– effective 1 July 2012 (continued)

continued... 3) specified the maximum quantity or period of supply to be dispensed at any one time. 4) For trial periods each Community Pharmaceutical on the Prescription must be endorsed with either “Close Control Trial” or “CCT” and the period of supply included e.g. CC Trial 1 week. C) Pharmaceutical Supply Management More frequent dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met: i) PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Community Pharmaceutical(s) “Close Control” without prescriber endorsement for a specified time; and ii) the dispensing pharmacist has: 1) clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words “Close Control” or “CC”; and 2) initialled the annotation in their own handwriting; and 3) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification. If a dispensing frequency is expressly stated in the Medicines Act, Medicines Regulations or Pharmacy Services Agreement a pharmacy can dispense at that specified dispensing frequency. However, no claim shall be made to any DHB for subsidised payment for dispensing fees in any case where dispensing occurs more frequently than authorised by the provisions of the Schedule. 15 Dispensing Frequency Rule The Pharmaceutical Schedule specifies for community patients a default period of supply for each Community Pharmaceutical. “Frequent Dispensing” means dispensing: • in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or • in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of A), or B) or C) apply. • The Dispensing Frequency Rule defines patient groups or medicines eligible for more frequent dispensing periods; and the conditions that must be met to enable any claim for payment of handling fees for the additional dispensings made. A. Frequency of dispensing for persons in residential care Pharmaceuticals can be dispensed in quantities of not less than 28 days to: • any person whose placement in a Residential Disability Care institution is funded by the Ministry of Health or a DHB; or • a person assessed as requiring long term residential care services and residing in an age related residential care facility; on the request of the person, their agent or caregiver or community residential service provider, provided the following conditions are met: I. the quantity or period of supply to be dispensed at any one time is not less than 28 days’ supply (except under conditions outlined in B.i below); and II. the prescribing Practitioner or dispensing pharmacist has 1) included the name of the patient’s residential placement or facility on the prescription; and 2) included the patient’s NHI number on the prescription; and 3) specified the maximum quantity or period of supply to be dispensed at any one time. Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with B.(i) below.

continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules– effective 1 July 2012 (continued)

continued... B. Flexible periods of supply for trial periods or safety The Schedule specifies for community patients a default length of dispensing (monthly/three monthly/ six monthly) for each pharmaceutical. If a pharmacist considers more frequent dispensing is required, this can occur as follows: • For LTC patients dispensing frequency can occur as often as the dispensing pharmacist deems appropriate to meet the patients compliance and adherence needs; • For non-LTC patients dispensing frequency should be no more often than monthly. If more frequent dispensings than monthly are necessary for non-LTC patients under this rule, prescriber approval is required. Verbal approval is acceptable, provided that it is annotated by the pharmacist on the prescription and dated. Note this does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement, Pharmaceutical Schedule or under parts i) Trial Periods or ii) safety and co-prescribed medicines below. Pharmacy would claim handling fees only on repeats under the above scenarios. Prescribers can request, and pharmacists may dispense a higher frequency of dispensing in the following circumstances: i) Trial Periods The Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient’s first changed Prescription only);and all of the following conditions must be met: The prescribing Practitioner has: • endorsed each Community Pharmaceutical on the Prescription clearly with the words “Trial Period”, or “Trial”; and • specified the maximum quantity or period of supply to be dispensed at any one time. All of the following conditions must be met: The Community Pharmaceutical has been prescribed for a patient who is not a resident in a Penal Institution.

ii) Safety and co-prescribed medicines A. The Community Pharmaceutical is any of the following: a) a tri-cyclic antidepressant; or b) an antipsychotic; or c) a benzodiazepine; or d) a Class B Controlled Drug; or e) codeine (includes combination products) f) buprenorphine with naloxone All of the following conditions must be met: The Community Pharmaceutical has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in clause A above. The prescribing Practitioner has: • Assessed clinical risk and determined the patient requires more a frequent period of dispensing than specified in the Pharmaceutical Schedule; and • specified the maximum quantity or period of supply to be dispensed at any one time. B. The Community Pharmaceutical is co-prescribed with one of the community pharmaceuticals listed above on the safety list and has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in clause A above. The Dispensing Pharmacist has: • Assessed clinical risk and determined the patient requires a more frequent period of dispensing than specified in the Pharmaceutical Schedule; • annotated the prescription with the amended dispensing quantity and frequency and the criteria for doing so. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules – effective 1 July 2012 (continued)

continued... C. Pharmaceutical Supply Management More frequent dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met: i) PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Community Pharmaceutical(s) “out of stock” without prescriber endorsement for a specified time; and ii) the dispensing pharmacist has: 1) clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words “out of stock” or “OOS”; and 2) initialled the annotation in their own handwriting; and 3) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification. Note – no claim shall be made to any DHB for subsidised dispensing where dispensing occurs more frequently than specified by PHARMAC to manage the supply management issue. NOTE patients who have had more frequent dispensings due to being “intellectually impaired, frail, infirm or unable to manage their medicines” will continue to receive the same frequency of dispensings until they are assessed to see if they are eligible for additional support under the Long-Term Care service. The structure of the remainder fee payment provides funding for pharmacy to continue to provide more frequent dispensings for patients until they are assessed. 21 3.1.7 If a Community Pharmaceutical: a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words “unstable medicine” and has specified the maximum quantity that may be dispensed at any one time; or b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words “unstable medicine” and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or c) is Close Control Under the Dispensing Frequency Rule, The actual quantity dispensed will be subsidised in accordance with any such specification. Oral Contraceptives 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed: a) in Lots as specified in on the Prescription if the Community Pharmaceutical is Close Control is Under the Dispensing Frequency Rule; or b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed. 3.2.4 Where a Community Pharmaceutical in on a Prescription is Close Control is Under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy. SECTION F: PART I A Community Pharmaceutical identified with a ❋ within the other sections of the Pharmaceutical Schedule: a) is exempt from any requirement to dispense in Monthly Lots; b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is Close Control Under the Dispensing Frequency Rule. A Community Pharmaceutical that is an oral contraceptive and that is identified with a ❋ within the other sections of the Pharmaceutical Schedule: a) is exempt from any requirement to dispense in Monthly Lots; b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is Close Control Under the Dispensing Frequency Rule.

▲

207

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules – effective 1 July 2012 (continued)

207 SECTION F: PART II: CERTIFIED EXEPTIONS AND ACCESS ECEMPTIONS TO MONTHLY DISPENSING A Community Pharmaceutical, other than a Community Pharmaceutical identified with a ❋ within the others sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if: a) the Community Pharmaceutical is identified with a s within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies “certified exemption”. In endorsing/annotating the Prescription items for a certified exemption, the prescriber/pharmacist is certifying that: i) the patient wishes to have the medicine dispensed in a quantity greater than a Monthly Lot; and ii) the patient has been stabilised on the same medicine for a reasonable period of time; and iii) the prescriber/pharmacist has reason to believe the patient will continue on the medicine and is compliant; or b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet: ii) Have limited physical mobility; iii) Live and work more than 30 minutes from the nearest pharmacy by their normal form of transport; iiii) Are relocating to another area; iiv) Are travelling extensively and will be out of town when the repeat prescriptions are due; or Section F: Part III: Flexible and Variable Dispensing Periods for Pharmacy A Community Pharmaceutical, other than a Community Pharmaceutical identified with a ❋ within the others sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions: a) for stock management where the original pack(s) result in dispensing greater than 30 days supply, b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identified with a ❋ please refer to Section F; Part II Note – the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 July 2012

128 LITHIUM CARBONATE Tab 250 mg ............................................................................ 34.30 Tab 400 mg ........................................................................... 12.83 500 100 ✔ Lithicarb Lithicarb FC ✔ Lithicarb Lithicarb FC

198

AMINOACID FORMULA WITHOUT PHENYALANINE – Special Authority see 1108 – Hospital pharmacy [HP3] Liquid (berry) ......................................................................... 15.65 62.5 ml OP ✔ PKU Lophlex LQ 10 31.20 125 ml OP ✔ PKU Lophlex LQ 20 Liquid (citrus) .......................................................................... 15.65 62.5 ml OP ✔ PKU Lophlex LQ 10 31.20 125 ml OP ✔ PKU Lophlex LQ 20 Liquid (orange) ....................................................................... 15.65 62.5 ml OP ✔ PKU Lophlex LQ 10 31.20 125 ml OP ✔ PKU Lophlex LQ 20

Effective 1 May 2012

31 KETONE BLOOD BETA-KETONE ELECTRODES – Maximum of 20 strip per prescription Test strip – Not on a BSO .......................................................... 7.07 10 strip OP ✔ Freestyle Optium Ketone Optium Blood Ketone Test Strips BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 meter per prescription b) 1) A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005 or is prescribed for a pregnant woman with diabetes. 2) Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly. Meter ....................................................................................... 9.00 1 ✔ Freestyle Optium Optium Xceed BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. SensoCard blood glucose test strips are subsidised only if prescribed for a patient who is severely visually impaired and is using a SensoCard Plus Talking Blood Glucose Monitor. Blood glucose test strips ......................................................... 21.65 50 test OP ✔ Freestyle Optium Optium 5 second test GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1087 Inj 1 g ..................................................................................... 62.50 1 ✔ Gemcitabine Actavis 1000 Inj 200 mg .............................................................................. 12.50 1 ✔ Gemcitabine Actavis 200

143

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name – effective 1 May 2012 (continued)

165 SODIUM CROMOGLYCATE Aerosol inhaler, 5 mg per dose CFC-free .................................. 28.07 112 dose OP ✔ Intal Forte CFC Free Vicrom

Changes to Sole Subsidised Supply

Effective 1 July 2012

For the list of new Sole Subsidised Supply products effective 1 July 2012 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 14-21.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 July 2012

50 98 DIGOXIN ❋ Tab 62.5 µg – Up to 30 tab available on a PSO ......................... 5.56 200 ✔ Lanoxin PG ❋ Tab 250 µg – Up to 30 tab available on a PSO .......................... 6.05 100 ✔ Lanoxin Note – Lanoxin PG tab 62.5 µg, 240 tab pack, and Lanoxin tab 250 µg 240 tab pack, remain subsidised. SULINDAC – Additional subsidy by Special Authority see SA1038 – Retail pharmacy ❋ Tab 100 mg ............................................................................. 5.32 100 (17.10) ❋ Tab 200 mg ............................................................................. 6.72 100 (30.20)

Daclin Daclin

Effective 1 June 2012

28 CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement ................................... 10.95 14 (23.30) Klamycin a) Maximum of 14 tab per prescription b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly. Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxycillin or metronidazole. GLYCERYL TRINITRATE ❋ Oral pump spray 400 µg per dose – Up to 250 dose available on a PSO ............................................................................... 4.45 CEFUROXIME SODIUM Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement ..................................................................... 6.96 (10.71)

250 dose OP ✔ Nitrolingual Pumpspray

5 Zinacef

CEFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. Inj 500 mg ............................................................................... 3.99 5 (5.00) Hospira Inj 1 g ....................................................................................... 3.99 5 (8.00) Hospira QUININE SULPHATE ❋ Tab 200 mg ............................................................................ 15.95 (17.20) TEMOZOLOMIDE – Special Authority see SA1063 – Retail pharmacy Cap 5 mg ............................................................................... 16.00 Cap 20 mg ............................................................................. 72.00 Cap 100 mg ......................................................................... 350.00 Cap 250 mg .......................................................................... 820.00 250 Q 200 5 5 5 5 ✔ Temodal ✔ Temodal ✔ Temodal ✔ Temodal

113 148

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 June 2012 (continued)

173 PHARMACY SERVICES – May only be claimed once per patient ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Lostaar is 2397145 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Arrow-Losartan is 2397153 1 fee 1 fee ✔ BSF Lostaar ✔ BSF Arrow-Losartan & Hydrochlorothiazide

Effective 1 May 2012

31 38 85 97 173 188 SODIUM NITROPRUSSIDE – Maximum of 50 strip per prescription ❋ Test strip – Not on a BSO ........................................................ 14.14 CALCIUM CARBONATE ❋ Tab 1.25 g (500 mg elemental).................................................. 6.38 ❋ Tab 1.5 g (600 mg elemental) ................................................... 7.66 ORNIDAZOLE Tab 500 mg ........................................................................... 12.38 20 strip OP ✔ Ketostix 250 250 10 ✔ Calci-Tab 500 ✔ Calci-Tab 600 ✔ Tiberal ✔ Ethics Ibuprofen ✔ BSF Bicalaccord

IBUPROFEN – Additional subsidy by Special Authority see SA1038 – Retail pharmacy ❋ Tab 200 mg ............................................................................ 12.75 1,000 PHARMACY SERVICES ❋ Brand switch fee ....................................................................... 0.01 The Pharmacode for BSF Bicalaccord is 2397137 1 fee

PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1100 – Hospital pharmacy [HP3] Liquid (strawberry) .................................................................... 1.60 200 ml OP ✔ NutriniDrink Liquid (vanilla)........................................................................... 1.60 200 ml OP ✔ NutriniDrink PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1100 – Hospital pharmacy [HP3] Liquid (chocolate) ..................................................................... 1.60 200 ml OP ✔ NutriniDrink Multifibre Liquid (strawberry) ................................................................... 1.60 200 ml OP ✔ NutriniDrink Multifibre Liquid (vanilla) .......................................................................... 1.60 200 ml OP ✔ NutriniDrink Multifibre AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 – Hospital pharmacy [HP3] Liquid (tropical) ...................................................................... 30.00 250 ml OP ✔ Easiphen AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA1108 – Retail pharmacy Powder ................................................................................... 23.38 100 g OP ✔ Metabolic Mineral Mixture

188

198 198

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 August 2012

33 URSODEOXYCHOLIC ACID – Special Authority see SA1188 – Retail pharmacy Cap 300 mg – For ursodeoxycholic acid oral liquid formulation refer, page 175 .................................................................... 71.50 100 METOPROLOL TARTRATE ❋ Inj 1 mg per ml, 5 ml .............................................................. 24.00 (34.00) ZINC AND CASTOR OIL Oint BP...................................................................................... 3.83 5.11 CLINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement - Retail pharmacy Specialist............................................................................... 9.90 TETRABENAZINE Tab 25 mg ........................................................................... 178.00 RIZATRIPTAN Tab orodispersible 10 mg .......................................................... 1.80 (17.56) 5 Betaloc 500 g PSM

✔ Actigall

52 62

16 112 3

✔ Dalacin C ✔ Xenazine 25

115 125

Maxalt Melt

154

OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA1016 – Retail pharmacy Inj 50 µg per ml, 1 ml ............................................................. 19.24 5 (25.65) Hospira (43.50) Sandostatin Inj 100 µg per ml, 1 ml ........................................................... 36.38 5 (48.50) Hospira 81.00 Sandostatin Inj 500 µg per ml, 1 ml ......................................................... 131.25 5 (175.00) Hospira (399.00) Sandostatin

Effective 1 September 2012

52 METOPROLOL SUCCINATE ❋ Tab long-acting 23.75 mg ........................................................ 0.96 (7.50) ❋ Tab long-acting 47.5 mg .......................................................... 1.41 (7.50) ❋ Tab long-acting 95 mg ............................................................. 2.42 (7.50) ❋ Tab long-acting 190 mg ............................................................ 4.66 (7.50) 30 30 30 30 ✔ Myloc CR Betaloc CR ✔ Myloc CR Betaloc CR ✔ Myloc CR Betaloc CR ✔ Myloc CR Betaloc CR

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted – effective 1 September 2012 (continued)

69 ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab 30 µg with levonorgestrel 150 µg and 7 inert tab – Up to 84 tab available on a PSO .............................................. 2.45 (6.62) (14.49) (16.50)

84 Levlen ED Monofeme Nordette 28 Microgynon 30 ED

Items to be Delisted – effective 1 October 2012

170 179 BRIMONIDINE TARTRATE ❋ Eye Drops 0.2%......................................................................... 6.45 ACETYLCYSTEINE – Retail pharmacy-Specialist Inj 200 mg per ml, 10 ml ....................................................... 137.06 (255.35) 5 ml OP 10 Hospira ✔ AFT

Effective 25 November 2012

51 ATENOLOL ❋ Tab 50 mg ............................................................................. 12.36 ❋ Tab 100 mg ........................................................................... 21.46 1,000 1,000 ✔ Atenolol Tablet USP ✔ Atenolol Tablet USP

Effective 1 December 2012

32 33 52 79 82 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g x 12.7 mm ...................................................................... 11.75 ❋ 31 g x 5 mm .......................................................................... 11.75 ❋ 31 g x 6 mm .......................................................................... 11.75 ❋ 31 g x 8 mm .......................................................................... 11.75 100 100 100 100 ✔ SC Profi-Fine ✔ SC Profi-Fine ✔ Fine Ject ✔ SC Profi-Fine

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g x 12.7 mm needle ............................ 13.00 100 ✔ DM Ject ❋ Syringe 0.3 ml with 31 g x 8 mm needle ................................. 13.00 100 ✔ DM Ject ❋ Syringe 0.5 ml with 29 g x 12.7 mm needle ............................ 13.00 100 ✔ DM Ject ❋ Syringe 0.5 ml with 31 g x 8 mm needle ................................. 13.00 100 ✔ DM Ject ❋ Syringe 1 ml with 29 g x 12.7 mm needle ............................... 13.00 100 ✔ DM Ject ❋ Syringe 1 ml with 31 g x 8 mm needle .................................... 13.00 100 ✔ DM Ject PROPRANOLOL ❋ Tab 40 mg ................................................................................ 4.65 GESTRINONE – Retail pharmacy-Specialist Cap 2.5 mg .......................................................................... 101.87 AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium clavulanate 125 mg – Up to 30 tab available on a PSO ........................... 26.00 INDOMETHACIN ❋ Suppos 100 mg ...................................................................... 14.50 100 8 OP ✔ Cardinol ✔ Dimetriose

100 30

✔ Synermox ✔ Arthrexin

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted – effective 1 December 2012 (continued)

142 CLADRIBINE – PCT only – Specialist Inj 2 mg per ml, 5 ml ............................................................. 873.00 1 ✔ Litak S29

Effective 1 January 2013

43 DABIGATRAN Cap 110 mg .......................................................................... 148.00 60 ✔ Pradaxa Cap 150 mg ......................................................................... 148.00 60 ✔ Pradaxa Note – these are the bottles Pharmacode 2377578 (110 mg cap) and 2377551 (150 mg cap) PHENTOLAMINE MESYLATE ❋ Inj 10 mg per ml, 1 ml ............................................................. 17.97 (31.65) NANDROLONE DECANOATE – Retail pharmacy-Specialist Inj 50 mg per ml, 1 ml ............................................................. 21.16 5 Regitine 1 ✔ Deca-Durabolin Orgaject S29

48 73

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 July 2012

16 ACITRETIN ( price) Cap 10 mg .............................................................................. 35.95 Cap 25 mg .............................................................................. 85.40 AMINO ACID FORMULA ( price) Powder (unflavoured) .............................................................. 53.00 Powder (vanilla) ...................................................................... 53.00 18 100 100 400 g 400 g Neotigason Neotigason Elecare Elecare LCP Elecare

ATENOLOL (removal of note) Note: HSS Status has been transferred to Atenolol Tablet USP tab 50 mg and 100 mg from Pacific Atenolol. Pacific Atenolol remains listed. Tab 50 mg – 1% DV May-10 to 2012......................................... 6.18 500 Pacific Atenolol 12.36 1,000 Atenolol Tablet USP Tab 100 mg – 1% DV May-10 to 2012..................................... 10.73 500 Pacific Atenolol 21.46 1,000 Atenolol Tablet USP Note – Atenolol Tablet USP 50 mg and 100 mg to be delisted 25 November 2012. ATRACURIUM BESYLATE ( price and continuation of HSS) Inj 10 mg per ml, 2.5 ml – 1% DV Sep-12 to 2015 .................... 6.13 Inj 10 mg per ml, 5 ml – 1% DV Sep-12 to 2015 ....................... 9.19 BENZATHINE BENZYLPENICILLIN (addition of HSS) Inj 1.2 mega u per 2.3 ml – 1% DV Sep-12 to 2015............... 315.00 BUPRENORPHINE WITH NALOXONE (new listing) Tab sublingual 2 mg with naloxone 0.5 mg .............................. 57.40 Tab sublingual 8 mg with naloxone 2 mg ............................... 166.00 CABERGOLINE (new listing) Tab 0.5 mg – 1% DV Sep-12 to 2015 ....................................... 6.25 25.00 CHLORAMPHENICOL ( price and continuation of HSS) Eye drops 0.5% – 1% DV Sep-12 to 2015 ................................. 1.20 CROTAMITON ( price and continuation of HSS) Crm 10% – 1% DV Sep-12 to 2015 ........................................... 3.48 CYCLIZINE HYDROCHLORIDE ( price and continuation of HSS) Tab 50 mg – 1% DV Sep-12 to 2015 ........................................ 0.59 5 5 10 28 28 2 8 10 ml 20 g 10 Tracrium Tracrium Bicillin LA Suboxone Suboxone Dostinex Dostinex Chlorafast Itch-Soothe Nausicalm

20 21

24 26 26 27

DABIGATRAN Cap 110 mg .......................................................................... 148.00 60 Pradaxa Cap 150 mg .......................................................................... 148.00 60 Pradaxa Note – Pradaxa cap 110 mg (p’code 2377578) and cap 150 mg (p’code 2377551) bottle presentations to be delisted 1 September 2012

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II - effective 1 July 2012 (continued)

28 DEXTROSE (discontinuation) Inj 50%, 50 ml – 1 % DV Sep-11 to 2014 ................................ 10.85 1 Biomed Note – Biomed inj 50%, 50 ml to be delisted 1 September 2012. Biomed's inj 50%, 10 ml and 90 ml remain available. DILTIAZEM HYDROCHLORIDE (addition of HSS) Tab 30 mg – 5% DV Sep-12 to 2015 ........................................ 4.60 Tab 60 mg – 5% DV Sep-12 to 2015 ........................................ 8.50 DOPAMINE HYDROCHLORIDE ( price and continuation of HSS) Inj 40 mg per ml, 5 ml – 1% DV Sep-12 to 2015 ..................... 69.77 ENOXAPARIN SODIUM ( price and continuation of HSS) Inj 20 mg – 1% DV Sep-12 to 2015 ....................................... 37.24 Inj 40 mg – 1% DV Sep-12 to 2015 ........................................ 49.69 Inj 60 mg – 1% DV Sep-12 to 2015 ........................................ 74.91 Inj 80 mg – 1% DV Sep-12 to 2015 ........................................ 99.86 Inj 100 mg – 1% DV Sep-12 to 2015 .................................... 125.06 Inj 120 mg – 1% DV Sep-12 to 2015 .................................... 155.40 Inj 150 mg – 1% DV Sep-12 to 2015 .................................... 177.60 ETIDRONATE DISODIUM ( price and continuation of HSS) Tab 200 mg – 1% DV Sep-12 to 2015 .................................... 15.80 FELODIPINE (new listing) Tab long-acting 2.5 mg – 1% DV Sep-12 to 2015 ..................... 2.90 Tab long-acting 5 mg – 1% DV Sep-12 to 2015 ........................ 3.10 Tab long-acting 10 mg – 1% DV Sep-12 to 2015 ...................... 4.60 Note – Felo 5 ER and Felo 10 ER to be delisted 1 September 2012. FENTANYL CITRATE ( price and continuation of HSS) Inj 50 µg per ml, 2 ml – 1% DV Sep-12 to 2015 ........................ 4.50 Inj 50 µg per ml, 10 ml – 1% DV Sep-12 to 2015 .................... 11.77 FLUCLOXACILLIN SODIUM ( price and continuation of HSS) Grans for oral liq 125 mg per 5 ml – 1% DV Sep-12 to 2015 ..... 2.49 Grans for oral liq 250 mg per 5 ml – 1% DV Sep-12 to 2015 ..... 3.25 FUROSEMIDE ( price and continuation of HSS) Tab 40 mg – 1% DV Sep-12 to 2015 ...................................... 10.25 GENTAMICIN SULPHATE ( price and continuation of HSS) Inj 40 mg per ml, 2 ml – 1% DV Sep-12 to 2015 ....................... 6.50 GLUCAGON HYDROCHLORIDE (new listing) Inj 1 mg syringe kit .................................................................. 32.00 100 100 10 10 10 10 10 10 10 10 100 30 30 30 Dilzem Dilzem Martindale Clexane Clexane Clexane Clexane Clexane Clexane Clexane Arrow-Etidronate Plendil ER Plendil ER Plendil ER

29 30

32 32

10 10 100 ml 100 ml 1,000 10 1

Boucher and Muir Boucher and Muir AFT AFT Diurin 40 Pfizer Glucagen Hypokit ABM ABM Hydroxocobalamin

34 35 35 37

HYDROXOCOBALAMIN ( price, brand name change and continuation of HSS) Inj 1 mg per ml, 1 ml – 1% DV Sep-12 to 2015 ......................... 5.10 3

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II - effective 1 July 2012 (continued)

38 IDARUBICIN HYDROCHLORIDE ( price and continuation of HSS) Inj 5 mg – 1% DV Sep-12 to 2015 ........................................ 100.00 Inj 10 mg – 1% DV Sep-12 to 2015 ...................................... 200.00 INSULIN ASPART (new listing) Inj 100 iu per ml, 3 ml prefilled pen .......................................... 52.15 LATANOPROST (new listing) Eye drops 50 µg per ml – 1% DV Sep-12 to 2015 ..................... 1.99 LITHIUM CARBONATE (new listing) Tab 250 mg – 1% DV Sep-12 to 2015 .................................... 34.30 Tab 400 mg – 1% DV Sep-12 to 2015 .................................... 12.83 MESALAZINE ( price and continuation of HSS) Enema 1 g per 100 ml – 1% DV Sep-12 to 2015 ..................... 44.12 METHADONE HYDROCHLORIDE (continuation of HSS) Oral liq 2 mg per ml – 1% DV Sep-12 to 2015 ( price) ............. 5.55 Oral liq 5 mg per ml – 1% DV Sep-12 to 2015 ........................... 5.55 Oral liq 10 mg per ml – 1% DV Sep-12 to 2015 ( price) ........... 6.55 1 1 5 2.5 ml 500 100 7 200 ml 200 ml 200 ml Zavedos Zavedos NovoMix 30 FlexPen Hysite Lithicarb FC Lithicarb FC Pentasa Biodone Biodone Forte Biodone Extra Forte

38 41 43

44 44

METOPROLOL SUCCINATE ( price) Tab long-acting 23.75 mg ......................................................... 7.50 30 Betaloc CR Tab long-acting 47.5 mg ........................................................... 7.50 30 Betaloc CR Tab long-acting 95 mg .............................................................. 7.50 30 Betaloc CR Note - Betaloc CR tab long-acting 23.75 mg, 47.5 mg and 95 mg to be delisted 1 September 2012 METOPROLOL SUCCINATE ( price) Tab long-acting 190 mg ............................................................ 7.50 Note - Betaloc CR tab long-acting 190 mg to be delisted 1 September 2012 MIRTAZAPINE ( price and addition of HSS) Tab 30 mg – 1% DV Sep-12 to 2015 ........................................ 8.78 Tab 45 mg – 1% DV Sep-12 to 2015 ...................................... 13.95 MOMETASONE FUROATE ( price and addition of HSS) Crm 0.1% – 1% DV Sep-12 to 2015 .......................................... 1.78 3.42 Oint 0.1% – 1% DV Sep-12 to 2015 .......................................... 1.78 3.42 PHENTOLAMINE MESYLATE (discontinuation) Inj 10 mg per ml, 1 ml ............................................................. 31.65 Note – Regitine inj 10 mg per ml, 1 ml to be delisted 1 September 2012. PIOGLITAZONE ( price and continuation of HSS) Tab 15 mg – 1% DV Sep-12 to 2015 ........................................ 1.50 Tab 30 mg – 1% DV Sep-12 to 2015 ........................................ 2.50 Tab 45 mg – 1% DV Sep-12 to 2015 ........................................ 3.50 30 Betaloc CR

30 30 15 g 45 g 15 g 45 g 1

Avanza Avanza m-Mometasone m-Mometasone m-Mometasone m-Mometasone Regitine

28 28 28

Pizaccord Pizaccord Pizaccord

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II - effective 1 July 2012 (continued)

54 PROMETHAZINE HYDROCHLORIDE ( price and addition of HSS) Tab 10 mg - 1% DV Sep-12 to 2015 ........................................ 1.99 Tab 25 mg - 1% DV Sep-12 to 2015 ......................................... 2.99 QUETIAPINE ( price) Tab 25 mg .............................................................................. 10.50 Tab 100 mg ............................................................................ 21.00 Tab 200 mg ............................................................................ 36.00 Tab 300 mg ............................................................................ 60.00 QUINAPRIL WITH HYDROCHLOROTHIAZIDE (addition of HSS) Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Aug-12 to 2015 ...................................................... 3.37 Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Aug-12 to 2015 ...................................................... 4.57 RECOMBINANT COAGULATION FACTOR VIIA (new listing) Combination pack (powder and diluent for inj) 1 mg............ 1,163.75 Combination pack (powder and diluent for inj) 2 mg............ 2,327.50 Combination pack (powder and diluent for inj) 5 mg............ 5,818.75 RISPERIDONE ( price) Tab 0.5 mg ............................................................................... 2.86 Tab 1 mg ................................................................................ 16.92 Tab 2 mg ................................................................................ 33.84 Tab 3 mg ................................................................................ 50.78 Tab 4 mg ................................................................................ 67.68 Oral liq 1 mg per ml ................................................................. 25.26 ROCURONIUM BROMIDE (new listing) Inj 10 mg per ml, 5 ml – 1% DV Sep-12 to 2015 ..................... 38.25 50 50 90 90 90 90 Allersoothe Allersoothe Quetapel Quetapel Quetapel Quetapel

30 30 1 1 1 20 60 60 60 60 30 ml 10

Accuretic 10 Accuretic 20 NovoSeven RT NovoSeven RT NovoSeven RT Risperdal Risperdal Risperdal Risperdal Risperdal Risperdal DBL Rocuronium Bromide

Note – Arrow-Rocuronium inj 10 mg per ml, 5 ml to be delisted 1 September 2012 57 ROCURONIUM BROMIDE ( price) Inj 10 mg per ml, 5 ml ............................................................ 38.25 10 Note – Arrow-Rocuronium inj 10 mg per ml, 5 ml to be delisted 1 September 2012 ROXITHROMYCIN ( price and continuation of HSS) Tab 150 mg – 1% DV Sep-12 to 2015 ...................................... 7.48 Tab 300 mg – 1% DV Sep-12 to 2015 .................................... 14.40 STANDARD SUPPLEMENT ORAL FEED (POWDER) ( price) Powder (chocolate) ................................................................. 13.00 Powder (vanilla) ...................................................................... 13.00 50 50 900 g 900 g Arrow-Rocuronium

Arrow-Roxithromycin Arrow-Roxithromycin Ensure Ensure

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II - effective 1 July 2012 (continued)

64 VENLAFAXINE ( price ) Cap 37.5 mg .......................................................................... 15.84 Tab 37.5 mg .......................................................................... 12.67 Cap 75 mg .............................................................................. 31.67 Tab 75 mg ............................................................................. 19.00 Cap 150 mg ............................................................................ 38.82 Tab 150 mg ............................................................................ 23.41 VINORELBINE ( price and continuation of HSS) Inj 10 mg per ml, 1 ml – 1% DV Sep-12 to 2015 ..................... 12.85 Inj 10 mg per ml, 5 ml – 1% DV Sep-12 to 2015 ..................... 64.25 28 28 28 28 28 28 1 1 Efexor XR Arrow-Venlafaxine XR Efexor XR Arrow-Venlafaxine XR Efexor XR Arrow-Venlafaxine XR Navelbine Navelbine

Effective 1 June 2012

18 AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium clavulanate 125 mg ... 26.00 Note – Synermox tab to be delisted 1 August 2012 100 Synermox

ATENOLOL Tab 50 mg .............................................................................. 12.36 1, 000 Tab 100 mg ............................................................................ 21.46 1, 000 Note – Atenolol Tablet USP 50 mg and 100 mg to be delisted 25 November 2012 AZITHROMYCIN Grans for oral liq 200 mg per 5 ml ........................................... 13.20 CLADRIBINE Inj 2 mg per ml, 5 ml ............................................................. 873.00 Note – Litak inj 2 mg per ml, 5 ml to be delisted 1 August 2012 DEXAMETHASONE Tab 1 mg – 1% DV Aug-12 to 2015 .......................................... 5.87 Tab 4 mg – 1% DV Aug-12 to 2015 .......................................... 8.16 EPIRUBICIN Inj 2 mg per ml, 25 ml – 1% DV Aug-12 to 2015 ..................... 39.38 15 ml 1

Atenolol Tablet USP Atenolol Tablet USP

19 25

Zithromax Litak

100 100 1

Douglas Douglas

DBL Epirubicin Hydrochloride Inj 2 mg per ml, 50 ml – 1% DV Aug-12 to 2015 ..................... 58.20 1 DBL Epirubicin Hydrochloride Inj 2 mg per ml, 100 ml – 1% DV Aug-12 to 2015 .................. 94.50 1 DBL Epirubicin Hydrochloride Note – Epirubicin Ebewe inj 2 mg per ml, 25 ml, 50 ml and 100 ml to be delisted 1 August 2012 39 INSULIN PEN NEEDLES 29 g × 12.7 mm ..................................................................... 11.75 100 SC Profi-Fine 31 g × 5 mm .......................................................................... 11.75 100 SC Profi-Fine 31 g × 8 mm .......................................................................... 11.75 100 SC Profi-Fine Note – SC Profi-Fine 29g x 12.7 mm, 31g x 5 mm and 31 g x 8 mm to be delisted 1 August 2012

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II - effective 1 June 2012 (continued)

39 INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE Syringe 0.3 ml with 29 g × 12.7 mm needle .......................... 13.00 100 DM Ject Syringe 0.3 ml with 31 g × 8 mm needle ............................... 13.00 100 DM Ject Syringe 0.5 ml with 29 g × 12.7 mm needle .......................... 13.00 100 DM Ject Syringe 0.5 ml with 31 g × 8 mm needle ............................... 13.00 100 DM Ject Syringe 1 ml with 29 g × 12.7 mm needle ............................. 13.00 100 DM Ject Syringe 1 ml with 31 g × 8 mm needle .................................. 13.00 100 DM Ject Note – DM Ject syringe 0.3 ml with 29 g x 12.7 mm needle, 0.3 ml with 31 g x 8 mm needle, 0.5 ml with 29 g x 12.7 mm needle, 0.5 ml with 31 g x 8 mm needle, 1 ml with 29 g x 12.7 mm needle and 1 ml with 31 g x 8 mm needle to be delisted 1 August 2012 METOPROLOL SUCCINATE ( price) Tab long-acting 23.75 mg ......................................................... 0.96 30 Myloc CR Tab long-acting 47.5 mg ........................................................... 1.41 30 Myloc CR Tab long-acting 95 mg .............................................................. 2.42 30 Myloc CR Tab long-acting 190 mg ............................................................ 4.66 30 Myloc CR Note – Myloc CR tab long acting 23.75 mg, 47.5 mg, 95 mg and 190 mg to be delisted 1 September 2012 MYCOPHENOLATE MOFETIL ( price) Tab 500 mg ........................................................................... 60.00 Cap 250 mg ............................................................................ 60.00 OXALIPLATIN Inj 50 mg – 1% DV Aug-12 to 2015 ........................................ 15.32 Inj 100 mg – 1% DV Aug-12 to 2015 ...................................... 25.01 Note – Oxaliplatin Ebewe inj 50 mg and 100 mg to be delisted 1 August 2012 52 56 60 PARECOXIB Inj 40 mg .............................................................................. 100.00 RECOMBINANT FACTOR VIII Inj 3,000 IU ........................................................................ 3,000.00 SODIUM NITROPRUSSIDE Test strip ................................................................................... 6.00 10 1 50 Dynastat Kogenate FS Accu-Chek Ketur-Test 50 100 1 1 Myaccord Myaccord Oxaliplatin Actavis 50 Oxaliplatin Actavis 100

Effective 1 May 2012

16 ACETYLCYSTEINE ( price and addition of HSS ) Inj 200 mg per ml, 10 ml – 1% DV Jul-12 to 2015................. 178.00 BARIUM SULPHATE (amended brand name) Oral suspension 2.2%, 250 ml .............................................. 175.00 10 Martindale Acetylcysteine CP Plus+ CT Plus+

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II - effective 1 May 2012 (continued)

20 BISOPROLOL FUMARATE Tab 2.5 mg ............................................................................... 3.88 Tab 5 mg .................................................................................. 4.74 Tab 10 mg ................................................................................ 9.18 BLOOD GLUCOSE DIAGNOSTIC TEST METER Meter ....................................................................................... 9.00 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP Blood glucose test strips ........................................................ 21.65 BRIMONIDINE TARTRATE Eye drops 0.2% – 1% DV Jul-12 to 2014 .................................. 6.45 Note – AFT brimonidine tartrate eye drops 0.2% to be delisted 1 July 2012 DORNASE ALFA Nebuliser soln, 2.5 mg per 2.5 ml amp .................................. 250.00 KETONE BLOOD BETA-KETONE ELECTRODES Test strips ................................................................................. 7.07 30 30 30 1 Bosvate Bosvate Bosvate Freestyle Optium Optium Xceed Freestyle Optium Optium 5 second test Arrow-Brimonidine

50 test

5 ml

29 40

6 10 strip

Pulmozyme Freestyle Optium Ketone Optium Blood Ketone Test Strips

METOPROLOL SUCCINATE ( price and addition of HSS) Tab long-acting 23.75 mg – 1% DV Sep-12 to 2015 ................. 0.96 30 Metoprolol - AFT CR Tab long-acting 47.5 mg – 1% DV Sep-12 to 2015 ................... 1.41 30 Metoprolol - AFT CR Tab long-acting 95 mg – 1% DV Sep-12 to 2015 ...................... 2.42 30 Metoprolol - AFT CR Tab long-acting 190 mg – 1% DV Sep-12 to 2015 .................... 4.66 30 Metoprolol - AFT CR Note – Betaloc CR and Myloc CR tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg to be delisted 1 September 2012 METOPROLOL TARTRATE Tab 50 mg – 1% DV Aug-12 to 2015 ...................................... 16.00 Tab 100 mg – 1% DV Aug-12 to 2015 .................................... 21.00 METOPROLOL TARTRATE ( price) Tab long-acting 200 mg – 1% DV Aug-12 to 2015 .................. 18.00 PROPYLTHIOURACIL Tab 50 mg .............................................................................. 35.00 SALBUTAMOL (HSS suspended) Oral liq 2 mg per 5 ml – 1% DV Sep-10 to 2013 ......................... 1.99 TETRABENAZINE Tab 25 mg – 1% DV Jul 12 to 2015 ...................................... 178.00 100 60 28 100 150 ml 112 Lopresor Lopresor Slow-Lopresor PTU Salapin Motetis

46 55 58 62

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Effective 1 April 2012

17 AMINO ACID FORMULA Powder (vanilla) ...................................................................... 56.00 Powder (unflavoured) .............................................................. 56.00 AMINOACID FORMULA WITHOUT PHENYLALANINE Liquid (berry) .......................................................................... 13.10 Liquid (orange) ........................................................................ 13.10 Liquid (unflavoured) ................................................................ 13.10 400 g 400 g 125 ml 125 ml 125 ml Neocate Advance Neocate Gold PKU Anamix Junior LQ PKU Anamix Junior LQ PKU Anamix Junior LQ

Section H changes to Part II - effective 1 April 2012 (continued)

23 CEFACLOR MONOHYDRATE Cap 250 mg ............................................................................ 24.57 Note: Cefaclor Sandoz cap 250 mg to be delisted 1 June 2012 DABIGATRAN Cap 110 mg. ......................................................................... 148.00 Cap 150 mg ......................................................................... 148.00 Note: This is a new listing of blister packed capsules. New pharmacode. ENTERAL FEED 1.5 KCAL/ML Liquid ........................................................................................ 7.00 ENTERAL FEED 2 KCAL/ML Liquid ........................................................................................ 5.50 FLUDARABINE PHOSPHATE Tab 10 mg – 1% DV Jun-12 to 2015 ..................................... 433.50 100 Ranbaxy-Cefaclor

60 60

Pradaxa Pradaxa

30 30 33 37

1,000 ml 500 ml 20

Nutrison Energy Nutrison Concentrated Fludara Oral

HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND CARBOHYDRATE Powder (vanilla) ...................................................................... 35.50 300 g KetoCal LAPATINIB DITOSYLATE Tab 250 mg ....................................................................... 1,899.00 PROPRANOLOL Tab 10 mg ............................................................................... 3.65 Tab 40 mg ............................................................................... 4.65 PAEDIATRIC ENTERAL FEED WITH FIBRE 0.75 KCAL/ML Liquid ........................................................................................ 4.00 PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML Liquid ........................................................................................ 6.00 70 100 100 500 ml Tykerb Apo-Propranolol Apo-Propranolol Nutrini Low Energy Multi Fibre Nutrini Energy Multi Fibre

41 51

500 ml

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II - effective 1 April 2012 (continued)

52 PAZOPANIB Tab 200 mg ....................................................................... 1,334.70 Tab 400 mg ....................................................................... 2,669.40 PRAMIPEXOLE HYDROCHLORIDE Tab 0.125 mg – 1% DV Jun-12 to 2013 .................................... 1.95 Tab 0.25 mg – 1% DV Jun-12 to 2013 ...................................... 2.40 Tab 0.5 mg ............................................................................... 4.20 54 PRASUGREL Tab 5 mg .............................................................................. 108.00 Tab 10 mg ............................................................................ 120.00 PREMATURE BIRTH FORMULA Powder ..................................................................................... 0.75 PRETERM POST-DISCHARGE INFANT FORMULA Powder ................................................................................... 15.25 30 30 30 30 30 Votrient Votrient Dr Reddy’s Pramipexole Dr Reddy’s Pramipexole Dr Reddy’s Pramipexole Effient Effient S26LBW Gold RTF S-26 Gold Premgro

28 28 100 ml 400 g

54 54 60

STANDARD SUPPLEMENT ORAL FEED (POWDER) 1.0KCAL/ML (amended chemical name) Powder (chocolate) ................................................................... 9.50 900 g Ensure 10.22 Sustagen Hospital Formula Powder (vanilla) ........................................................................ 9.50 900 g Ensure 10.22 Sustagen Hospital Formula STANDARD SUPPLEMENT ORAL FEED (POWDER) (new listing) Powder (vanilla) ........................................................................ 9.50 TRIAMCINOLONE ACETONIDE ( price and addition of HSS) Inj 10 mg per ml, 1 ml – 1% DV Jun-12 to 2014...................... 21.90 Inj 40 mg per ml, 1 ml – 1% DV Jun-12 to 2014 ..................... 53.79 900 g 5 5 Fortisip Kenacort-A Kenacort-A40

60 63

Section H changes to Part III

Effective 1 June 2012

68 INDOMETHACIN Supp 100 mg S29 For any indication approved by the hospital service

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Index

Pharmaceuticals and brands A ABM Hydroxocobalamin ............................... 36, 55 Accu-Chek Ketur-Test .................................. 24, 59 Acitretin ....................................................... 37, 54 Act-HIB .............................................................. 22 Accuretic 10 ...................................................... 57 Accuretic 20 ...................................................... 57 Acetazolamide ................................................... 34 Acetylcysteine........................................ 41, 52, 59 Actigall ........................................................ 40, 51 ADT Booster ...................................................... 22 Alendronate sodium ........................................... 31 Alendronate sodium with cholecalciferol ............. 31 Alfacalcidol ........................................................ 29 Allersoothe................................................... 39, 57 Aluminium hydroxide.......................................... 29 Alu-Tab .............................................................. 29 Amino acid formula .......................... 27, 39, 54, 61 Aminoacid formula with minerals without phenylalanine ...................................... 50 Aminoacid formula without phenylalanine 47, 50, 61 Amoxycillin clavulanate ................................ 52, 58 Anastrozole ........................................................ 32 Apo-Clopidogrel ................................................. 29 Apo-Moclobemide.............................................. 31 Apo-Propranolol ................................................. 61 Aremed .............................................................. 32 Arimidex ............................................................ 32 Aromasin ........................................................... 32 Arrow-Brimonidine ................................. 25, 34, 60 Arrow-Etidronate .......................................... 37, 55 Arrow-Meloxicam............................................... 31 Arrow-Rocuronium ............................................ 57 Arrow-Roxithromycin ................................... 37, 57 Arrow-Sertraline ................................................. 31 Arrow-Venlafaxine XR................................... 38, 58 Arthrexin ............................................................ 52 Atenolol ................................................. 52, 54, 58 Atenolol Tablet USP................................ 52, 54, 58 Atracurium besylate ........................................... 54 Auranofin ........................................................... 24 Ava 20 ED.......................................................... 22 Ava 30 ED.......................................................... 30 Avanza......................................................... 38, 56 Azithromycin ................................................ 24, 58 Azopt ................................................................. 34 B Bacillus calmette-guerin vaccine......................... 22 Barium sulphate ................................................. 59 Batrafen ............................................................. 32 BCG Vaccine ...................................................... 22 Benzathine benzylpenicillin ................................. 54 Betaloc ........................................................ 40, 51 Betaloc CR ....................................... 36, 39, 51, 56 Bicillin LA........................................................... 54 Bimatoprost ....................................................... 34 Biodone ....................................................... 37, 56 Biodone Extra Forte ...................................... 37, 56 Biodone Forte..................................................... 56 Bisoprolol fumarate ...................................... 25, 60 Blood glucose diagnostic test meter ............. 47, 60 Blood glucose diagnostic test strip ............... 47, 60 Boostrix ............................................................. 22 Bosvate ....................................................... 25, 60 Brimonidine tartrate .................... 25, 34, 39, 52, 60 Brimonidine tartrate with timolol maleate............. 35 Brinzolamide ...................................................... 34 BSF Arrow-Losartan & Hydrochlorothiazide ........ 50 BSF Bicalaccord ................................................. 50 BSF Lostaar ....................................................... 50 Buprenorphine with naloxone........................ 23, 54 C Cabergoline.................................................. 37, 54 Calci-Tab 500 .................................................... 50 Calci-Tab 600 .................................................... 50 Calcium carbonate ............................................. 50 Carboplatin ........................................................ 25 Cardinol ............................................................. 52 Carvedilol ........................................................... 30 Cefaclor monohydrate ........................................ 61 Cefazolin sodium ............................................... 49 Cefuroxime sodium ............................................ 49 Champix ............................................................ 26 Chlorafast .................................................... 39, 54 Chloramphenicol .......................................... 39, 54 Cholvastin .......................................................... 30 Ciclopirox olamine.............................................. 32 Ciclopiroxolamine............................................... 32 Cladribine..................................................... 53, 58 Clarithromycin.................................................... 49 Clexane ........................................................ 36, 55 Clindamycin ................................................. 40, 51 Clopidogrel ........................................................ 29 Combigan .......................................................... 35 Cosopt ............................................................... 34 CP Plus+ .......................................................... 59 Crotamiton ................................................... 36, 54 CT Plus+ .......................................................... 59 Cyclizine hydrochloride ................................ 38, 54 D Dabigatran ....................................... 26, 52, 54, 61 Daclin ................................................................ 49 Dalacin C ..................................................... 40, 51 DBL Carboplatin ................................................. 25

Index

Pharmaceuticals and brands DBL Doxorubicin ................................................ 25 DBL Epirubicin Hydrochloride ....................... 24, 58 DBL Rocuronium Bromide .................................. 57 Deca-Durabolin Orgaject .................................... 53 Dexamethasone ........................................... 40, 58 Dextrose ............................................................ 55 Diamox .............................................................. 34 Digoxin .............................................................. 49 Dilatrend ............................................................ 30 Diltiazem hydrochloride ...................................... 55 Dilzem ............................................................... 55 Dimetriose ......................................................... 52 Diptheria and tetanus vaccine ............................. 22 Diptheria, tetanus, and pertussis vaccine ............ 22 Diptheria, tetanus, pertussis, and polio vaccine ... 22 Diptheria, tetanus, pertussis, polio, hepatitis b, and haemophilus influenzae type b vaccine...... 22 Diurin 40 ...................................................... 36, 55 DM Ject ....................................................... 52, 59 Domperidone ..................................................... 40 Dopamine hydrochloride .................................... 55 Dornase alfa................................................. 41, 60 Dorzolamide hydrochloride ................................. 34 Dorzolamide hydrochloride with timolol maleate.. 34 Dostinex ...................................................... 37, 54 Doxorubicin ....................................................... 25 DP-Anastrozole .................................................. 32 Dr Reddy’s Ondansetron .................................... 32 Dr Reddy’s Pramipexole ..................................... 62 Dr Reddy’s Terbinafine ....................................... 31 Dynastat ............................................................ 59 Dynacirc-SRO .................................................... 30 E Easiphen ............................................................ 50 Effient .......................................................... 29, 62 Elecare .................................................. 27, 39, 54 Elecare LCP ........................................... 27, 39, 54 Efexor XR ..................................................... 38, 58 Eformoterol fumarate.......................................... 39 Enoxaparin sodium....................................... 36, 55 Ensure ................................................... 39, 57, 62 Enteral feed 1.5 Kcal/ml ..................................... 61 Enteral feed 2 kcal/ml ......................................... 61 Epirubicin..................................................... 24, 58 Escitalopram ...................................................... 31 Ethics Ibuprofen ................................................. 50 Ethinyloestradiol with levonorgestrel . 22, 30, 39, 52 Etidronate disodium ..................................... 37, 55 Evista................................................................. 31 Exemestane ....................................................... 32 Extensively hydrolysed formula........................... 27 F Felodipine ........................................ 22, 26, 36, 55 Fentanyl citrate............................................. 37, 55 Ferro-F-Tabs ...................................................... 29 Ferro-tab ............................................................ 29 Ferrous fumarate ................................................ 29 Ferrous fumarate with folic acid .......................... 29 Ferrum H............................................................ 29 Finasteride ......................................................... 30 Fine Ject ............................................................ 52 Flucloxacillin sodium .................................... 37, 55 Fludarabine phosphate ....................................... 61 Fludara Oral ....................................................... 61 Foradil ............................................................... 39 Fortisip .............................................................. 62 Fosamax ............................................................ 31 Fosamax Plus .................................................... 31 Freestyle Optium .......................................... 47, 60 Furosemide .................................................. 36, 55 G Gardasil ............................................................. 22 Gemcitabine Actavis 200.............................. 32, 47 Gemcitabine Actavis 1000............................ 32, 47 Gemcitabine Actavis s29 .................................... 32 Gemcitabine hydrochloride ........................... 32, 47 Gemfibrozil ........................................................ 30 Gentamicin sulphate ..................................... 37, 55 Gestrinone ......................................................... 52 Glucagen Hypokit ......................................... 36, 55 Glucagon hydrochloride ............................... 36, 55 Glyceryl trinitrate ................................................ 49 H Habitrol .............................................................. 26 Haemophilus influenzae type b vaccine ............... 22 HBvaxPro ........................................................... 22 Hepatitis b vaccine ............................................. 22 High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate ................................................... 61 Human papillomavirus vaccine ........................... 22 Hydroxocobalamin ....................................... 36, 55 Hysite .................................................... 34, 39, 56 I Ibuprofen ........................................................... 50 Idarubicin hydrochloride ............................... 38, 56 Indomethacin ............................................... 52, 62 Infanrix-hexa ...................................................... 22 Infanrix-IPV ........................................................ 22 Insulin pen needles....................................... 52, 58 Insulin syringes, disposable with attached needle ......................................... 52, 59 Intal Forte CFC Free ............................................ 48

Index

Pharmaceuticals and brands Insulin aspart ............................................... 22, 56 Iron polymaltose ................................................ 29 Isradipine ........................................................... 30 Itch-Soothe .................................................. 36, 54 K Kenacort-A......................................................... 62 Kenacort-A40..................................................... 62 KetoCal .............................................................. 61 Ketone blood beta-ketone electrodes ............ 47, 60 Ketostix.............................................................. 50 Klamycin............................................................ 49 Kogenate FS....................................................... 59 L Lanoxin .............................................................. 49 Lanoxin PG ........................................................ 49 Lapatinib ditosylate ...................................... 33, 61 Latanoprost............................................ 34, 39, 56 Letara ................................................................ 32 Letrozole ............................................................ 32 Levlen ED .............................................. 30, 39, 52 Lipazil ................................................................ 30 Litak ............................................................ 53, 58 Lithicarb ............................................................ 47 Lithicarb FC ........................................... 38, 47, 56 Lithium carbonate .................................. 38, 47, 56 Lopresor ...................................................... 40, 60 Loxalate ............................................................. 31 Loxamine ........................................................... 31 Lumigan ............................................................ 34 M Magnesium sulphate .......................................... 29 Martindale Acetylcysteine ............................. 41, 59 Maxalt Melt .................................................. 40, 51 Measles, mumps and rubella vaccine ................. 23 Meloxicam ......................................................... 31 Meningococcal a, c, y and w-135 vaccine .......... 23 Menomune......................................................... 23 Mesalazine ................................................... 36, 56 Metabolic Mineral Mixture................................... 50 Methadone hydrochloride ............................. 37, 56 Metoprolol - AFT CR..................................... 40, 60 Metoprolol succinate ...... 36, 39, 40, 51, 56, 59, 60 Metoprolol tartrate .................................. 40, 51, 60 Microgynon 30 ED ................................. 30, 39, 52 Mirtazapine .................................................. 38, 56 m-Mometasone............................................ 37, 56 M-M-R II ............................................................ 23 Moclobemide ..................................................... 31 Mometasone furoate .................................... 37, 56 Monofeme ............................................. 30, 39, 52 Motetis .............................................................. 60 Motilium ............................................................ 40 Multivitamins ..................................................... 29 Myaccord .................................................... 40, 59 Mycophenolate mofetil ................................. 40, 59 Myloc CR ............................................... 39, 51, 59 N Nandrolone decanoate........................................ 53 Nardil ................................................................. 31 Nausicalm.................................................... 38, 54 Navelbine ..................................................... 38, 58 Neocate ............................................................. 27 Neocate Advance ......................................... 27, 61 Neocate Gold ............................................... 27, 61 Neocate LCP ...................................................... 27 Neotigason .................................................. 37, 54 NeuroKare.......................................................... 29 Nicotine ............................................................. 26 Nitrolingual Pumpspray ...................................... 49 Nordette 28 ............................................ 30, 39, 52 Norethisterone ................................................... 37 Noriday 28 ......................................................... 37 NovoMix 30 FlexPen ..................................... 22, 56 NovoSeven RT ................................................... 57 NutriniDrink ........................................................ 50 NutriniDrink Multifibre ......................................... 50 Nutrini Energy Multi Fibre.................................... 61 Nutrini Low Energy Multi Fibre ............................ 61 Nutrison Concentrated ........................................ 61 Nutrison Energy ................................................. 61 O Octreotide (somatostatin analogue) .............. 41, 51 Ondansetron ...................................................... 32 One-Alpha .......................................................... 29 Optium 5 second test ................................... 47, 60 Optium Blood Ketone Test Strips .................. 47, 60 Optium Xceed .............................................. 47, 60 Oral feed (powder) ............................................. 39 Ornidazole.......................................................... 50 Oxaliplatin Actavis 50 ................................... 24, 59 Oxaliplatin Actavis 100 ................................. 24, 59 Oxaliplatin .................................................... 24, 59 Oxis Turbuhaler .................................................. 39 P Pacific Atenolol .................................................. 54 Paediatric enteral feed with fibre 0.75 Kcal/ml..... 61 Paediatric enteral feed with fibre 1.5Kcal/ml........ 61 Paediatric oral feed 1.5Kcal/ml ........................... 50 Paediatric oral feed with fibre 1.5Kcal/ml ............ 50 Paediatric Seravit ............................................... 29 Parecoxib........................................................... 59 Parnate .............................................................. 31 Paroxetine hydrochloride .................................... 31 Pazopanib .......................................................... 62 65

Index

Pharmaceuticals and brands Pentasa ....................................................... 36, 56 Pepti Junior Gold................................................ 27 Pharmacy services............................................. 50 Phenelzine sulphate............................................ 31 Phentolamine mesylate ................................ 53, 56 Pioglitazone ........................................... 29, 36, 56 Pizaccord............................................... 29, 36, 56 PKU Anamix Junior LQ ....................................... 61 PKU Lophlex LQ ................................................. 47 PKU Lophlex LQ 10 ............................................ 47 PKU Lophlex LQ 20 ............................................ 47 Plendil ER ........................................ 22, 26, 36, 55 Pneumococcal (PCV13) vaccine ........................ 23 Pneumococcal polysaccharide vaccine .............. 23 Pneumococcal vaccine ...................................... 23 Pneumovax 23 ................................................... 23 Potassium iodate ............................................... 29 Pradaxa ........................................... 26, 52, 54, 61 Pramipexole hydrochloride ................................. 62 Prasugrel ..................................................... 29, 62 Pravastatin ......................................................... 30 Premature birth formula................................ 26, 62 Preterm post-discharge infant formula ................ 62 Prevenar 13 ....................................................... 23 Promethazine hydrochloride ......................... 39, 57 Propranolol .................................................. 52, 61 Propylthiouracil ............................................ 25, 60 PTU ............................................................. 25, 60 Pulmozyme .................................................. 41, 60 Q Q 200 ................................................................ 49 Quetapel ...................................................... 38, 57 Quetiapine.................................................... 38, 57 Quinapril with hydrochlorothiazide ...................... 57 Quinine sulphate ................................................ 49 R Raloxifene hydrochloride .................................... 31 Ranbaxy-Cefaclor............................................... 61 Recombinant coagulation factor VIIa................... 57 Recombinant factor VIII ...................................... 59 Regitine ....................................................... 53, 56 Ridaura S29 ....................................................... 24 Risperdal ..................................................... 38, 57 Risperidone.................................................. 38, 57 Rizatriptan.................................................... 40, 51 Rocuronium bromide ......................................... 57 Roxithromycin.............................................. 37, 57 S S-26 Gold Premgro ............................................ 62 S26LBW Gold RTF ....................................... 26, 62 Salapin .............................................................. 60 Salbutamol................................................... 25, 60 Sandostatin .................................................. 41, 51 SC Profi-Fine................................................ 52, 58 Sertraline ........................................................... 31 Slow-Lopresor ............................................. 40, 60 Sodium chloride ................................................. 32 Sodium chloride oral liquid ................................. 35 Sodium chromoglycate ...................................... 48 Sodium fluoride .................................................. 29 Sodium nitroprusside ............................. 24, 50, 59 Standard supplement oral feed (powder) ...... 57, 62 Suboxone .................................................... 23, 54 Sulindac............................................................. 49 Sunitinib ............................................................ 33 Sustagen hospital formula .................................. 62 Sutent ................................................................ 33 Synermox .................................................... 52, 58 Synflorix ............................................................ 23 T Tamsulosin hydrochloride .................................. 30 Tamsulosin-Rex ................................................. 30 Temodal ............................................................ 49 Temozolomide ................................................... 49 Terbinafine ......................................................... 31 Tetrabenazine............................................... 51, 60 Tiberal ............................................................... 50 Tracrium ............................................................ 54 Tranylcypromine sulphate .................................. 31 Travatan............................................................. 34 Travoprost ......................................................... 34 Triamcinolone acetonide .................................... 62 Trusopt .............................................................. 34 Tykerb ......................................................... 33, 61 U Ursodeoxycholic acid ................................... 40, 51 V Varenicline tartrate ............................................. 26 Venlafaxine .................................................. 38, 58 Ventolin ............................................................. 25 Vicrom ............................................................... 48 Vinorelbine ................................................... 38, 58 Vitadol C ............................................................ 29 Vitamin A with vitamins D and C ......................... 29 Vivonex Pediatric................................................ 27 Votrient .............................................................. 62 X Xenazine 25 ....................................................... 51 Z Zavedos ....................................................... 38, 56 Zinacef ............................................................... 49 Zinc and castor oil .................................. 30, 40, 51 Zithromax..................................................... 24, 58

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 July 2012

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 July 2012 Cumulative for May, June and July 2012 Section H cumulative for April, May, June and July 2012 Only annually for hard copy Schedule and Updates $55 www. schedule.…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.